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Abstract
Significance: Nuclear factor erythroid 2 (NFE2)-related factor 2 (NFE2L2, or NRF2) is a transcription factor
predominantly affecting the expression of antioxidant genes. NRF2 plays a significant role in the control of
redox balance, which is crucial in cancer cells. NRF2 activation regulates numerous cancer hallmarks, including
metabolism, cancer stem cell characteristics, tumor aggressiveness, invasion, and metastasis formation. We
review the molecular characteristics of the NRF2 pathway and discuss its interactions with the cancer hallmarks
previously listed.
Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway
are involved in carcinogenesis. Further, cancer-related changes (e.g., metabolic flexibility) that support cancer
progression were found to be redox- and NRF2 dependent.
Critical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2
are context dependent and essentially based on the specific molecular characteristics of the cancer in question.
Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The
biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes.
Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the
activity of the NRF2 system.
Future Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2
pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system
interferes with cytostatic drugs and their combinations. Antioxid. Redox Signal. 00, 000–000.
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Introduction
The redox balance in cells is tightly regulated to meetphysiological needs by balancing the abundance of pro-
oxidants and reductants. In cancer, the redox balance is
commonly dysregulated. However, whether the redox im-
balance induces or inhibits cancer formation and cell growth
is rather controversial, as the pro- or anticancer effects vary
between different cancers andmay change as a function of the
cancer type (48, 49, 73–75, 80, 95, 180, 183, 218, 225, 227,
295). Nuclear factor erythroid 2 (NFE2)-related factor 2
(NFE2L2, commonly referred to as NRF2) is a transcription
factor that plays a crucial role inmaintaining the expression of
antioxidant genes. Therefore, NRF2 is vital inmaintaining the
cellular redox balance.
NRF2 is present in model organisms such as Caenor-
habditis elegans and Drosophila melanogaster, which have
an antioxidant system similar to mammals, suggesting that
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the NRF2 pathway represents an evolutionary conserved
cytoprotective program (71). However, NRF2 signaling
spans beyond redox signaling toward metabolic pathways
and the induction of collective cellular changes exemplified
by cancer metabolism. In this review, we set out to provide a
critical focus on NRF2 activity in cancer. We discuss the
aberrant activation of NRF2 and its critical cellular targets.
The Molecular Determinants of NRF2 Signaling
The molecular structure of NRF2
NRF2 is a basic leucine zipper domain (bZIP) transcription
factor and contains a Cap’N’Collar structure. NRF2 com-
prises 605 amino acids and has a calculated molecular weight
of 68 kDa. However, recent studies claim that NRF2 may
have a higher apparent molecular weight (up to*130 kDa)
(155, 292). In our hands, the actual molecular weight of NRF2
and the proportions between the different molecular weight
isoforms vary between experimental models. Thus, the use of
validated antibodies is crucial in investigating NRF2.
The NRF2 transcription factor contains seven conserved
NRF2-ECH homology (Neh) domains, known as Neh1-
Neh7 (Fig. 1A). The Neh1 domain allows the binding of
NRF2 to the antioxidant response sequences (electrophilic
responsive/antioxidant-response elements [EpRE/ARE]; 5¢-
RTGABNNNGCR-3¢). The Neh2 domain, the major regu-
latory domain located in the N-terminal region of NRF2,
is essential for the Kelch-like ECH-associated protein 1
(KEAP1)-dependent degradation of NRF2 (see later). The
Neh2 domain possesses ETGE and DLG motifs, which are
responsible for direct interaction with the negative regula-
tor, KEAP1 (191, 192, 287). The Neh3, Neh4, and Neh5
domains are transactivation domains. Neh3 is located in the
C-terminal region of NRF2 and binds to the chromo-AT-
Pase/helicase DNA binding protein family member CHD6,
which functions as an NRF2 transcriptional coactivator
(204). Neh4 and Neh5 are responsible for NRF2-mediated
ARE transactivation by binding to a transcriptional coacti-
vator CREB-binding protein (130). The Neh6 domain is a
serine-rich region that regulates NRF2 stability. The redox-
insensitive Neh6 domain consists of two motifs (DSGIS and
DSAPGS) that are responsible for the binding of b-
transducin repeat-containing protein (b-TrCP). Phosphor-
ylation of the DSGIS motif by glycogen synthase kinase 3
(GSK3) enhances the ability of b-TrCP to ubiquitinate
NRF2 (37, 223). The Neh7 domain was shown to interact
with the retinoic acid receptor X receptor a (RAR a), which
represses NRF2 target gene expression (297).
The repressor protein of NRF2, KEAP1; the canonical
activation of the KEAP1-NRF2 pathway
The main function of NRF2 is to protect the cells against
exogenous and endogenous insults elicited by oxidative
stress, which impairs cell function by damaging intracellular
lipids, proteins, nucleic acids, and carbohydrates (45).
KEAP1 is a repressor of NRF2 located mainly in the cyto-
plasm, which acts as a substrate adaptor for Cul3-containing
E3 ubiquitin ligase (108, 202, 280). E3 ubiquitin ligase is
responsible for the ubiquitination of NRF2 followed by its
degradation in the proteasomes, resulting in low cellular
NRF2 levels under unstressed conditions (41, 145, 332).
KEAP1 contains five domains, including the amino-
terminal N-terminal region, the Broad complex/Tramtrack/
Bric-a-brac (BTB) domain, the intervening region (IVR), the
six Kelch/double glycine repeats (DGR), and the carboxy-
terminal (CTR) domain (Fig. 1B). The BTB domain interacts
with Cul3 and is required for KEAP1 dimerization (347). The
IVR contains several cysteine residues and regulates the ac-
tivity of KEAP1 (207). The Kelch/DGR domain maintains
the interaction between NRF2 and KEAP1 (191). The DGR
FIG. 1. Schematic representation of the domain structure of NRF2 and KEAP1 proteins. (A) NRF2 comprises seven
domains (Neh1–7). The Neh1 is responsible for DNA binding and dimerization with small Maf proteins. The Neh2 domain
contains DLG and ETGE motifs that interact with KEAP1. The Neh3, Neh4, and Neh5 domains are transactivation
domains; the Neh6 domain regulates NRF2 stability, and the Neh7 domain is responsible for RXRa binding. (B) KEAP1
contains five domains: the amino terminal NTR, CTR, and three major domains, BTB, IVR, and Kelch/DGR domains. The
BTB domain associates with Cul3 and mediates KEAP1 dimerization. The IVR domain contains cysteine residues and
connects the BTB and Kelch/DGR domains. The Kelch/DGR domain maintains the interaction between KEAP1 and NRF2.
BTB, Broad complex/Tramtrack/bric-a-brac; CTR, carboxy-terminal; DGR, double glycine repeats; IVR, intervening re-
gion; KEAP1, Kelch-like ECH-associated protein 1; Neh, NRF2-ECH homology; NFE2, nuclear factor erythroid 2; NRF2,
NFE2-related factor 2; NTR, N-terminal region; RXRa, retinoid X receptor a. Color images are available online.
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region recognizes ETGE andDLGmotifs in the Neh2 domain
of NRF2 protein.
Under normal conditions, NRF2 interacts with KEAP1
through the Neh2 domains (DLG and ETGE motifs), which
drive NRF2 to the Cul-3-RBx1-E3 (Cullin-3-ring box-1 E3)
ubiquitin ligase complex for degradation (108, 202, 280).
KEAP1 is a cysteine-rich protein; in humans, it contains 27
cysteine residues that can be modified by different oxidant and
electrophilic compounds (54, 190). The highly reactive cys-
teine residues, Cys151, Cys171, Cys273, and Cys288, are lo-
cated in the BTB-IVR domains of KEAP1 protein. Cysteines
are susceptible to oxidation and modification (e.g., alkylation
or Michael addition) of the cysteine thiols of KEAP1 and
NRF2 during oxidative stress is a key step in NRF2 activation
(184). Cys151 of KEAP1 was found to facilitate NRF2 activ-
ity, whereas Cys288was shown to diminishNRF2 activity (94,
321). Modification of redox-sensitive cysteines (Cys119,
Cys235) of NRF2 prevents KEAP1 recognition and binding
(93). Modification of those residues alters the conformation of
KEAP1, causing detachment of the DLG motif (low-affinity
binding site) from the KEAP1-NRF2 complex. However,
NRF2 remains in association with KEAP1 through the ETGE
motif (high-affinity binding site), according to the hinge and
latchmodel by Tong et al. (287, 288). This steric change, when
the DLG motif of KEAP1 releases NRF2, prevents the deg-
radation of NRF2.
During cellular stress, Sekhar and co-workers (251) sug-
gested that the binding between KEAP1 and Cul3 can also be
disrupted, leading to NRF2 escape from proteasomal degra-
dation. NRF2 can also be degraded and eliminated by
KEAP1-independent mechanisms with the help of b-TrCP,
which can recognize and bind to phosphorylated NRF2 and
trigger its ubiquitination and degradation (37, 223, 224). A
third degradation procedure has been reported in cirrhotic
liver, where endoplasmic reticulum stress triggers E3 ubi-
quitin ligase (namely, HRD1) interaction with NRF2 do-
mains, promoting NRF2 elimination (313). Subsequently,
free NRF2 translocates to the nucleus where it dimerizes with
transactivation partners [for instance, Small Maf protein
family (293) or Jun (289, 328)] and binds to the promoter
region of EpRE/ARE-response genes, inducing their tran-
scription (101, 219). After NRF2 exerts its effect in the nu-
cleus, it is phosphorylated by tyrosine kinases that promote
NRF2 nuclear export and cytosolic degradation (110).
Role of NRF2 in antioxidant defense
There are more than 200 NRF2-dependent target genes
identified in humans (186, 346). A more recent study sug-
gests that there might be more than 1000 genes regulated by
NRF2 (186). The majority of NRF2-dependent target genes
encode for detoxifying enzymes to overcome oxidative
damage of DNA, proteins, and lipids, for example, genes
involved in the synthesis of glutathione, antioxidant pro-
teins, drug-metabolizing enzymes, transporters, and nu-
merous other stress response proteins [for review, see Hayes
and Dinkova-Kostova (92) and Suzuki et al. (277)] (Fig. 2).
Oxidative, nitrosative, and electrophilic stress promote
NRF2 stabilization and activity. NRF2 maintains the appro-
priate intracellular reduced glutathione (GSH)/oxidized
FIG. 2. The classical KEAP1/NRF2 signaling pathway. Under basal conditions, KEAP1 binds to NRF2 and links NRF2
to the KEAP1-Cul3-E3 ubiquitin ligase complex, resulting in ubiquitination and degradation of NRF2. In response to stress,
KEAP1-NRF2 binding is disrupted, NRF2 is stabilized, and free NRF2 translocates to the nucleus, where it heterodimerizes
with the small Maf proteins, binds to AREs, and induces the transcription of its target genes. ARE, antioxidant response
element; Cul3, cullin 3; Gclc, glutamate-cysteine ligase catalytic subunit; Gclm, glutamate-cysteine ligase modifier subunit;
Gsr1, glutathione reductase 1; GST, glutathione S-transferase; Gpx2, glutathione peroxidase 2; G6pd, glucose-6-phosphate
dehydrogenase; Hmox1, heme oxygenase 1; Idh1, isocitrate dehydrogenase 1; Me1, malic enzyme 1; Mrp1, multidrug
resistance-associated protein 1; NRF2 or Nfe2l2, nuclear factor E2-related factor 2; Nqo1, NAD(P)H quinone dehydro-
genase 1; Pgd, 6-phosphogluconate dehydrogenase; Srxn1, sulfiredoxin 1; Txn, thioredoxin; Txnrd1, thioredoxin reductase
1. Color images are available online.
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glutathione (GSSG) ratio by maintaining glutathione syn-
thesis and glutathione reduction. This is achieved through
controlling the expression of glutamate-cysteine ligase cat-
alytic (GCLC) and modifier (GCLM) subunits of the
glutamate-cysteine ligase (GCL) complex, which collec-
tively catalyze the rate-limiting step in GSH synthesis (99).
NRF2 also regulates the expression of glutathione reductase 1
(Gsr1) (282). Further, NRF2 regulates the expression of the
SLC7A11 (subunit of the cystine/glutamate antiporter system
Xc-), which imports cystine into cells in exchange for glu-
tamate, and hence, regulates cysteine and glutamate avail-
ability in cells (163). Finally, NRF2 regulates the pentose-
phosphate shunt and through that NADPH availability that is
needed for reducing GSSG (4, 35, 92, 159, 334).
Besides the regulation of glutathione levels, NRF2 controls
the expression of a broad set of enzymes that play a role in the
detoxification of H2O2, peroxide radicals, and oxidized thiols,
including glutathione peroxidase 2 (Gpx2) (88), thioredoxin
1 (Txn1), thioredoxin reductase 1 (Txnrd1), sulfiredoxin
1 (Srxn1) (2, 90), and glutathione S-transferases (282). Pro-
duction of NADPH, which is used as a cofactor by many
antioxidant systems in redox reactions, is also under the
control of NRF2. The expression of glucose-6-phosphate de-
hydrogenase (G6pd), 6-phosphogluconate dehydrogenase
(Pgd), isocitrate dehydrogenase 1 (Idh1), and malic enzyme 1
(Me1) is NRF2 dependent. Another prominent cytoprotective
enzyme regulated by NRF2 is heme oxygenase 1 (HMOX1),
the enzyme catalyzing the breakdown of heme molecules (7)
and catalase, which reduces H2O2 to water and oxygen.
Natural and synthetic inductors and inhibitors
of NRF2 signaling
Other small-molecule inhibitors and activators are vital in
fine-tuning NRF2 activity (184). In cancer, certain interme-
diates of cell metabolism can modulate the NRF2-KEAP1
system by introducing post-translational modifications into
NRF2 or KEAP1 that impact NRF2 function or stability. For
instance, the mutation of fumarate hydratase in papillary
renal cell carcinoma leads to fumarate accumulation, which
induces KEAP1 succination and NRF2 stabilization (209).
The inhibition of glycolysis and concomitant build-up of
glycolytic intermediates in several cell lines promote NRF2
activity through methylglyoxal-induced (elimination product
of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate)
formation of a covalent bond between arginines and cysteines
(so-called MICA modification) that leads to the dimeriza-
tion of KEAP1 (23). In glucose-free conditions, a decrease in
KEAP1 O-glycosylation with b-N-acetylglucosamine leads
to NRF2 accumulation in breast cancer cells (30). Finally,
glycation destabilizes NRF2 via increased proteasomal deg-
radation in hepatocellular carcinoma (HCC) (245).
Several artificial NRF2 activators function by disrupting
KEAP1-NRF2 interaction, including tert-butylhydroquinone
(166) or RA839 (310). Removing KEAP1 from the KEAP1-
NRF2 complex leads to stabilization and activation of NRF2.
The inhibition of the proteasome (e.g., by MG132) can pre-
vent the degradation of NRF2 (149). A food additive and pro-
carcinogen, butylated hydroxyanisole, can induce NRF2
(179) and NAD(P)H quinone dehydrogenase 1 (NQO1),
which boosts the expression of 8-Oxoguanine glycosylase
(OGG1) (268). Increased OGG1 prevents the oxidative ca-
tabolism of 4-hydroxyestradiol (4-OHE2) to the catechol
estrogen quinone metabolites, which readily reacts with
DNA to produce depurinated adducts. Superphysiological
concentrations of vitamin C can also decrease the nuclear/
cytosolic NRF2 ratio, indicating NRF2 activation (200).
A nucleoside analog antimetabolite, Cordycepin, down-
regulates NRF2 signaling and, consequently, increases the
cytoplasmic levels of oxygen-centered reactive species (ROS).
Cordycepin was employed as a radiosensitizer in breast
cancer in a preclinical study (56). Although this study did not
elucidate a mechanism of action, Cordycepin may induce
caveolin-1 (Cav-1) expression (119). Cav-1 can suppress
the NRF2-elicited effects by reducing manganese-dependent
superoxide dismutase (MnSOD) expression, an important
downstream target of the NRF2 pathway (86). In agreement
with this theory, epidemiologic nested case–control studies
show that Cav-1 and NRF2/MnSOD are inversely expressed
in cases of invasive ductal carcinoma, where low Cav-1 and
high NRF2 andMnSOD expression are associated with lower
5-year survival rates and the poorest prognosis (86).
The n-6 and n-3 polyunsaturated fatty acids (PUFAs)
serve as substrates for cyclooxygenases that synthesize
PUFA-derived hormones. One of the final products of the
cyclooxygenase-2 (COX-2) pathway, 15-deoxy-prostaglandin
J2 (15d-PGJ2), is switched on by inflammatory stimuli (258).
In breast cancer cells, NRF2 translocation to the nucleus is
induced by 15d-PGJ2, resulting in enhanced interaction be-
tween NRF2 with ARE (161) to drive the expression of a
variety of phase 2 detoxifying and antioxidant enzymes (131).
Nuclear accumulation and the transactivation of NRF2 ap-
pears to be dependent on the presence of the characteristic
cyclopentenone moiety in 15d-PGJ2 (161). The electrophilic
a,b-unsaturated carbonyl group, constituting the cyclopente-
none ring of 15d-PGJ2, is anticipated to bind covalently to
specific cysteine residues of the KEAP1molecule, resulting in
the liberation and nuclear translocation of NRF2 (59).
There is a firm link between the etiology of several cancers
and bacterial dysbiosis (65, 67, 76, 77, 98, 118, 150, 196). In
breast cancer, bacterial metabolites (estrogen metabolites,
short chain fatty acids, lithocholic acid [LCA], and cadav-
erine) were shown to play key roles in regulating the behavior
of cancer cells by influencing breast cancer stemness, anti-
cancer immunity, cancer cell migration, metastasis forma-
tion, epithelial-to-mesenchymal transitions, and cancer cell
metabolism (109, 149, 150, 194–196). Apparently, the ca-
pacity of the microbiome to synthesize these metabolites is
reduced in breast cancer as compared with controls (76, 150,
196). The secondary bile acid, LCA was shown to exert cy-
tostatic properties on breast cancer cells. Further, bacterial
LCA production is largely reduced in the early stages of
breast cancer (196). LCA reduces NRF2 expression, and the
consequent reduction in antioxidant defenses exerts cyto-
static properties in breast cancer. This mechanism is inef-
fective in nontransformed cells (149).
Hormones regulating NRF2 signaling
Hormones, such as gonadotropins and sex steroids
(follicle-stimulating hormone, luteinizing hormone, estro-
gen), can promote NRF2 signaling through the induction of
ROS [measured by dichlorofluorescein (DCF)—please note
that DCF autooxidation may produce reactive species and,
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hence, provide a false positive result (124, 236)] in ovarian
cancer (167). Follicle-stimulating hormone can further acti-
vate hypoxia-inducible factor 1 (HIF1) and vascular endo-
thelial growth factor (VEGF) to promote tumor angiogenesis
(339). Hormone regulation of NRF2 was found in ovarian
cancer and may also play a major role in the development of
other hormone-related cancers such as prostate and breast
cancer (122).
Noncanonical NRF2 activation
Noncanonical NRF2 activation is based on the presence of
proteins that activate NRF2 transcription by inducing the
disassembly of the NRF2-KEAP1 complex. Certain ETGE
motif-containing proteins can compete with KEAP1 for di-
merization with NRF2, to prevent NRF2 degradation. Pro-
teins that activate NRF2 include Wilms tumor gene on the X
chromosome (WTX, AMER1) (25), partner and localizer of
BRCA2 (PALB2) (181), dipeptidyl peptidase 3 (DPP3) (89),
Cyclin-dependent kinase 20 (CDK20) (300), sequestosome 1
(p62) (107), p21 (31), and additional proteins identified in
(89). The spectrum of competing proteins might represent a
divergence of oxidative stress-related and -unrelated cellular
signals, resulting in NRF2-induced cytoprotection.
Although several noncanonical activators of NRF2 were
described, only a few have been studied in the context of
cancer etiology, including kidney (25), breast (178), and lung
(89) cancers, and osteosarcoma (181). DPP3 contains an
ETGE motif, which binds to the Kelch domain of KEAP1 and
activates NRF2 (89) in breast cancer cells in response to ROS.
Overexpression of DPP3 in MCF7 cells causes accumulation
of NRF2 and promotes resistance to H2O2 and diquat (178).
Hast et al. (89) performed TCGA-based data mining analysis
in tumor gene expression datasets to assess DPP3 expression
in relation toNFE2L2 andKEAP1.DPP3 expression and copy
number were increased in NFE2L2 wild-type and KEAP1
mutant tumors as compared with NFE2L2 mutant or KEAP1
wild-type tumors. This implicates that DPP3 enhances NRF2
activity under conditions when KEAP1 activity is attenuated
by hypomorphic mutations. Consequently, the function of
NRF2 is amplified even though hypomorphic KEAP1 activity
is still able to suppress NRF2. On the other hand, NRF2 mu-
tations often lead to hyperactivation of NRF2 and eliminate
the need for additional amplifying factors. Further, this phe-
nomenonmight apply to other ETGE-containing proteins, too.
More recent research (32) identified family with sequence
similarity 129, member B (FAM129B) as another positive
regulator of NRF2 signaling, active in several cancer cell
lines. FAM129B contains DLG and ETGE sequences, and
FAM129B expression correlates with poor clinical outcome
in breast and lung cancers (32). Similarly, PALB2 competes
effectively with KEAP1 for NRF2 binding and the over-
expression of PALB2 induces NRF2 levels and transcription
via interaction with the nuclear NRF2-KEAP1 complex (181).
The depletion of PALB2 in vitro impairs NRF2 function.
Another example of noncanonical activation of NRF2 is
p21, a cyclin-dependent kinase inhibitor. In the cell model of
colorectal cancer, p21 can recognize and directly bind to the
DLG/ETGE motif of NRF2 to prevent NRF2 degradation.
Hence, the expression of antioxidant genes, such as HMOX1
an NQO1 (31), in response to H2O2 treatment is enhanced.
NRF2, in turn, can elevate p21 expression by binding to the
promoter region of p21, as demonstrated in a study focused
on lung carcinoma with deficient p53 (111).
During the initiation of the autophagy cascade, p62 binds
to KEAP1 and initiates NRF2 transactivation of target genes.
As an autophagy substrate, p62 can also interfere with NRF2-
KEAP1 interaction through binding to the DLG/ETGE motif
and activating NRF2 (107). The role of p62 in NRF2 trans-
activation was confirmed in hepatic adenoma (107), HCC
(261), breast and ovarian cancers (233, 315), and in glioma
(340). In contrast, in normal hepatocytes, NRF2 is degraded
under the same conditions (317). The expression of p62 and
oligomerization in the cytosol is also a negative prognostic
factor in HCC recurrence (317). In breast cancer, p62-
dependent NRF2 activation induces the proportions of CD44-
positive cancer stem cells (CSCs) that are associated with an
aggressive phenotype with enhanced tumor growth and ele-
vated therapeutic resistance (239).
Role of NRF2 in Cancer
Cancers and cancer cell behavior can be characterized
by cancer hallmarks (85), which contribute to the ability to
sustain proliferation and to evade cell death. NRF2, as a stra-
tegic cytoprotective factor, positively regulates several cancer
hallmarks, including the promotion of metastasis, evasion of
cell death, and metabolic changes. In normal cells, activation
of NRF2 complies with the period of acute detoxification;
whereas in cancer cells, a newly described phenomenon called
‘‘NRF2 addiction’’ occurs (144). NRF2 addiction refers to
sustainedNRF2 signaling due to genetic, epigenetic, or general
oncogenic signaling. There is growing experimental evidence
that NRF2 activation enhances cancer growth and increases
therapy resistance (14, 177) due to the expression of phase 1
and phase 2 drug-metabolizing enzymes (92) and multidrug-
resistance-associated transporters (Mrps) (185), which support
metastasis formation (100, 246), cancer growth (52, 232), and
poor survival (115, 178) (Fig. 3 and Table 1). It is interesting to
note that, despite the large number of examples where NRF2
activation is associated with negative outcomes, NRF2 over-
expression can support longer survival in certain cancers (58,
75, 80, 95, 128, 156, 172, 180, 277) (Fig. 4). In this article, we
will review the molecular prerequisites of aberrant NRF2
signaling in cancer.
Genetic mutations in KEAP1 and NRF2
The occurrence of somatic mutations in KEAP1, NRF2, or
Cul3 is the most well-known mechanism of sustained NRF2
activation in cancer (193). According to public genomic data-
bases,KEAP1 and NFE2L2 seem to be the most affected genes
in lung cancer, followed by esophageal and endometrial cancer,
as summarized (134). Studies assessing statistics of genetic
alterations in lung cancer (226) demonstrate frequent loss-of-
function (LOF) mutations in KEAP1 (213) and loss-of-
heterozygosity at the genetic locus of KEAP1 (266). KEAP1
missense or nonsense mutations have been also identified in
malignant melanoma (198), thyroid cancer (44), HCC (38),
endometrial carcinoma (311), and breast (203, 271) and ovarian
cancers (148). In summary, mutations of KEAP1 that confer
loss of function or hypomorphic function induceNRF2 activity.
Alleles of NRF2 that lead to its activation have been de-
scribed as well. The genetic mutation of NFE2L2 affecting
the DLG/ETGE motif of the Neh2 domain was shown in a
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lung cancer cell line (259), renal cell carcinoma (208), HCC
(81), skin cancer (142), and esophageal carcinoma (257). A
unique genetic mutation, deletion of the NFE2L2 exon 2, was
found to stabilize NRF2 and enhance its activity in nonsmall-
cell lung carcinoma (NSCLC) and head-neck cancer (78).
Moreover, copy number loss of Cul3 or inactivating mutation
of RBx1, which controls NRF2 degradation, was shown in
esophageal (170) and ovarian cancer (188), as well as in
thyroid (187) and renal cell carcinoma (208).
A recent study identified two single nucleotide polymor-
phisms of KEAP1 associated with shorter relapse-free sur-
vival in breast carcinoma (87). A study by Kova´cs et al. (149)
showed that NRF2 overexpression and the downregulation of
downstream pro-oxidant genes negatively correlates with
patient survival in nontriple negative breast cancer. Our
search in the TCGA-BRCA dataset revealed prominent am-
plification of DPP3 and p62 genes, which suggests amplifi-
cation of NRF2 activity in breast cancer by noncanonical
mechanisms (Fig. 5).
Epigenetic modifications of KEAP1 and NRF2
Epigenetic modification in KEAP1 or NFE2L2 promoter
regions can also contribute to NRF2 stabilization in many
cancers (122). Both hypo- and hypermethylation of the
NFE2L2 promoter have been reported. Hypomethylation, due
to the reduced expression of EZH2 methyltransferase, is as-
sociated with NRF2 overexpression in colon cancer (125).
Hypermethylation of the NFE2L2 promoter is associated with
prostate cancer (135) and leads to reduced NRF2 activity, a
rare example among malignant diseases. Bromodomain pro-
tein 4 (BRD4) was implicated in the transcriptional regulation
ofKEAP1. Thus, BRD4might represent a strong modulator of
the NRF2/KEAP1 pathway in prostate cancer (105).
Hypermethylation of the KEAP1 promoter (CpG islands)
is catalyzed by methyl-CpG-binding domain protein 1 and
ubiquitin-like, containing PHD and RING finger domains-1
(UHRF1), leading to reduced KEAP1 protein levels and
augmented expression of NRF2-dependent genes (3, 331).
KEAP1 hypermethylation is associated with lung (301), co-
lorectal (84), breast (16), prostate (337), thyroid (187), and
renal (61) cancers, as well as malignant glioma (201).
The regulatory role of microRNAs in NRF2 signaling
NRF2 and KEAP1 levels can be modulated at the post-
transcriptional level through altering mRNA splicing or
microRNA (miRNA) levels. In the breast cancer cell line,
MCF-7, miR-28 inhibits NRF2 actionwithout the contribution
of KEAP1 (324). ThemiRNAs, miR-507, miR-634, miR450a,
miR129–5p miR-340, miR-146b, and miR144, were reported
to directly suppress NRF2 activation in different cancer types,
including acute myeloid leukemia (AML) (274), breast cancer
(104), and esophageal cancer (320). In HCC, miR-144 sup-
pressed NRF2 levels (344); whereas in neuroblastoma, the
same miRNA induced ROS-induced apoptosis (341). Recent
studies demonstrate that miRNAs promote migration and
support malignant transformation in different neoplasias. For
example, miR-155 promotes lung cancer (28) and miR93a and
miR153 drive the malignant transformation of the breast (269,
296). Last but not least, NRF2 can influence and modulate the
expression of numerous miRNAs in tumors, creating a com-
plex feedback-regulatory system in humans (253).
Several miRNAs were shown to modulate KEAP1, NRF2,
and target gene translation or transcription. The miRNAs,
miR-432-3p and miR-200a, impair KEAP1 translation in
esophageal and breast carcinoma (6, 58); whereas miR-7 and
miR-148b increase the expression of NRF2-dependent anti-
oxidant genes (HMOX1 and GCLM) in neuroblastoma (123)
or elevate ROS production due to the repression of HIF1 and
NRF2 expression (220), respectively.
Oncogenic signaling
Although NRF2 activity promotes cancer progression by
various mechanisms, as previously discussed, we should
emphasize that NRF2 accumulation can only contribute to
FIG. 3. Mechanisms in-
volved in the aberrant ac-
tivation of KEAP1/NRF2
pathway in cancer. Color
images are available online.
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Table 1. Aberrant Activation of NRF2 in Cancer and NRF2-Addicted Cancer Types
Tissue or organ Cancer/cell type Mechanism of action Reference
Nerve system Malignant glioma Hypermethylation of KEAP1 promoter (201)
Neuroblastoma miR-7 inhibits KEAP1 expression (123)
miR-144 inhibits NRF2 and antioxidant
gene expression
(341)
Glioma p62 disrupts KEAP1-NRF2 complex (340)
Endoplasmatic reticulum stress induces NRF2 (27)
Bone Osteosarcoma PALB2 disrupts KEAP1-NRF2 complex (181)
Breast Breast carcinoma NRF2 promotes cell survival (178)
LOF mutation of KEAP1 (203, 271)
Hypermethylation of KEAP1 promoter (16)
miR-28 inhibits NRF2 expression (324)
miR-93a supports malignant transformation (269)
miR153 supports malignant transformation (296)
PI3K/AKT influence NRF2 signaling (239)
AMPK induces NRF2 target gene expression
and modulate autophagy
(294)
miR-200a targets KEAP1 and induces NRF2 (58)
Hypermethylation of KEAP1 promoter (84)
Overexpression of p62 facilitate tumorigenesis (233)
Colon Colorectal carcinoma Hypomethylation of NRF2 promoter (125)
PI3K/AKT influence NRF2 signaling (175)
LOF mutation of KEAP1 (271)
Head and neck Head and neck cancer Cul3 copy number loss (187)
Esophageal carcinoma Cul3 copy number loss (170)
miR-144 directly suppresses NRF2 (320)
Deletion of NRF2 exon 2 (142)
Genetic mutation of NRF2 affect DLG/ETGE motif (142, 257)
Hematologic
malignancies
AML Stress signaling induces NF-jB signaling (238)
Endoplasmatic reticulum stress induces
NRF2 signaling
(8)
Deletion of NRF2 exon 2 (78)
miR-144-3p suppresses NRF2 activation (274)
Lung NSCLC Hypermethylation of KEAP1 promoter (301)
Lung cancer miR-155 promotes malignant transformation (28)
p21 disrupts KEAP1-NRF2 connection (111)
DPP3 disrupts KEAP1-NRF2 connection (89)
CDK20 disrupts KEAP1-NRF2 connection (300)
K-RAS promotes ERK/MEK pathway (279)
PI3K/AKT influences NRF2 signaling (197)
Liver Hepatocellular carcinoma Genetic mutation of NRF2 affects DLG/ETGE motif (81)
miR-144 directly suppresses NRF2 (344)
p62 disrupts KEAP1-NRF2 complex (261)
AICAR induces NRF2 activity (264)
p62 disrupts KEAP1-NRF2 complex (107)
Skin Squamous cell carcinoma Deletion of NRF2 exon 2 (142)
Pancreas Pancreas adenocarcinoma Hypermethylation of KEAP1 promoter
through URHF1
(3, 331, 337)
Prostate Prostate cancer Hypermethylation of NRF2 promoter (105, 135)
Kidney Papillary renal
cell carcinoma
Hypermethylation of KEAP1 promoter (61)
Genetic mutation of NRF2 affects DLG/ETGE motif
FH disrupts KEAP1-NRF2 connection
(208, 209)
Wilms tumor K-RAS promotes ERK/MEK pathway (13)
Cell model of renal
cell carcinoma
miR-148b represses NRF2 and enhances ROS (220)
Clear renal cell carcinoma WTX disrupts KEAP1-NRF2 connection (25)
Ovary Ovarian cancer Cul3 copy number loss (188)
Hormone-induced NRF2 overexpression (144, 339)
p62 disrupts KEAP1-NRF2 complex (315)
Endoplasmatic reticulum stress induce
FGFR4/GSK3b/NRF2 axis
(167)
AKT, protein kinase B; AML, acute myeloid leukemia; AMPK, AMP-activated protein kinase; BRCA2, breast cancer type 2
susceptibility protein; CDK20, cyclin-dependent kinase 20; DPP3, dipeptidyl peptidase 3; FH, fumarate hydratase; GSK3b, glycogen
synthase kinase 3b; LOF, loss-of-function; MEK, mitogen-activated protein kinase kinase; NSCLC, nonsmall-cell lung carcinoma; p62,
sequestosome 1; PALB2, partner and localizer of BRCA2; PI3K, phosphoinositide 3-kinases; ROS, oxygen-centered reactive species;
WTX, Wilms tumor gene on the X chromosome.
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FIG. 4. Tumor NRF2 expression affects survival. Patient survival data were retrieved from the pan-cancer RNAseq
segment of the kmplot.com database (154). (A) Tumors where high expression of NRF2 prolongs survival. (B) Tumors
where high expression of NRF2 shortens survival. The y axis represents the probability for survival, whereas the x axis
represents time in months. Numerical values for the Kaplan-Mayer survival curves can be found in Table 3. The red line
depicts the high expression quartile of the population, while the black line depicts the low expression quartile. Color images
are available online.
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malignant proliferation in the presence of active oncogenic
signaling and, therefore, we refer to its role as the onco-
genic driver.Keap1-deficient mice develop cancer only in the
presence of oncogenic mutations, such as those in Kras/Hras
or Tp53 (113, 234). The contribution of NRF2 to carcino-
genesis differs between cancer types. For example, the
Kras:Tp53:Keap1 triple mutation is associated with an ag-
gressive phenotype in lung carcinoma in *30% of cases,
whereas in the pancreas this combination of mutations does
not initiate cancer but leads to fibrosis (83).
Recent evidence suggests that cancer-associated signaling
pathways can influence the activity of NRF2 by increasing its
mRNA level rather than improving its stability. In this re-
spect, K-Ras and B-Raf signaling pathways can enhance
NRF2mRNA levels to promote ROS elimination (52). K-Ras
promotes NRF2 transcription through the extracellular
signal–regulated kinase (ERK)/mitogen-activated protein
kinase kinase (MEK) pathway in NSCLC (279) and renal
carcinoma (13). The importance of Ras signaling is high-
lighted by the findings that H-Ras-activated HO-1 over-
expression is abolished by ERK inhibitors or NFE2L2
knockdown (13). In K-Ras-associated malignancies, the el-
evated expression of antioxidant genes (HMOX1 and NQO1)
is associated with an aggressive phenotype, whereas the
FIG. 5. Genetic aberrations of NRF2 signaling pathway members in breast carcinoma. (A) Chart depicting per-
centages of mutations and copy number variations (amplification and deletion, respectively) of NRF2, KEAP1, CUL3, and
several genes involved in noncanonical activation of NRF2 as discussed in the Strategic role of p62 in NRF2 signaling:
autophagy and metabolic rewiring section. The data are based on the TCGA portal search (data set TCGA BRCA, Ductal
and Lobular Neoplasms, containing 513 cases). (B) Mutation maps (lollipop plots) depicting positions of the mutations in
NRF2 (NFE2L2), KEAP1, and CUL3 proteins. The data are based on a cBIOPORTAL search, combining several studies
containing data on breast carcinoma samples. Color images are available online.
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elimination of NRF2 disrupts malignant progression and re-
stores sensitivity to cancer therapy (254). NRF2 signaling
also actively improves cancer survival by maintaining inde-
pendence of growth factors in K-Ras-associated malignan-
cies; in pancreatic ductal adenocarcinoma (PDAC), NRF2
signaling is upregulated, resulting in improved cancer sur-
vival via maintaining phosphorylated levels of EGFR and
ERBB2, and by maintaining intact mRNA translation effi-
ciency (33). Interestingly, NFE2L2 knockdown in normal
organoids was tolerated, whereas NRF2 knockdown was
detrimental in tumor-derived organoids.
The nuclear accumulation of NRF2 increases when dif-
ferent proliferative pathways are active (263, 278). Phos-
phoinositide 3-kinases (PI3K)/protein kinase B (AKT)
activation is associated with elevated NRF2 mRNA levels
and nuclear accumulation of NRF2, leading to increased cell
proliferation, survival, and metabolic reprogramming (197).
In breast cancer, PI3K/AKT activation, in response to es-
tradiol, is accompanied by elevated expression of NRF2 and,
consequently, increased expression of a large set of antioxi-
dant genes (79). As mentioned earlier, GSK3 can phosphor-
ylate NRF2 and induce its degradation by the Cult1-bTrCP
complex. When the PI3K-AKT pathway is active, AKT
phosphorylates and inactivates GSK3, leading to inactivation
of Cult1-bTrCP-driven NRF2 degradation in cancer cells
(37). Further, in Keap1-deficient mice, PI3K-AKT activation
leads to NRF2 nuclear accumulation and NRF2-driven cell
proliferation of hepatocytes (263).
NRF2 in unfolded protein response
Accumulation of unfolded proteins in the lumen of endo-
plasmic reticulum, termed endoplasmic reticulum stress,
activates the unfolded protein response (UPR) (235). En-
doplasmic reticulum stress and UPR are frequently found in
tumor cells due to nutrient deficiency, hypoxia, and exposure
to therapeutic agents. The association of UPR with the
KEAP1/NRF2 pathway has been investigated in both cancer
cells and normal cells. Starvation activates NRF2 through
AMP-activated protein kinase (AMPK) and through protein
kinase R-like endoplasmic reticulum kinase (PERK), which
is located in the endoplasmic reticulum membrane and in-
duced during UPR (40–42). NRF2 is phosphorylated by
PERK, which leads to the dissociation of the NRF2/KEAP1
complex and increased expression of ARE genes to promote
survival via reduced ROS levels (42).
In cancer, the PERK-NRF2 pathway drives endoplasmic
reticulum stress-resistance and multidrug resistance as dem-
onstrated in colorectal cancer (243), multiple myeloma (276),
and AML cells (8). Further, in oral (tongue) squamous car-
cinoma cells, heat shock 70 kDa protein 5 (GRP78) and
PERK-dependent activation of NRF2 induced Warburg-type
metabolism and maintained cancer-initiating cells indepen-
dently of ROS production (27). Moreover, fibroblast growth
factor 19, which is overexpressed in HCC, can promote the
cytoprotective FGFR4/GSK3b/NRF2 axis to protect against
endoplasmic reticulum stress (281).
NRF2 regulating specific aspects of cancer
metabolism
Cancer metabolism is usually perceived in the context of
maintaining high energy standards for growing cells and in-
cludes enhanced catabolic pathways, enhanced biosynthetic
pathways, and maintenance of redox homeostasis associated
with high substrate turnover. The primary function of NRF2
is still the regulation of oxidative damage. However, since a
number of NRF2 targets are rate-limiting enzymes in the
respective pathways, the function of NRF2 logically en-
compasses metabolic rewiring also. Indeed, several meta-
bolic pathways in NRF2-overexpressing cancer cells have
been described as elevated, including the pentose-phosphate
pathway (PPP), and nucleotide-, glutathione- (234), and
serine synthesis in a lung cancer (51) model. In this section,
we draw attention to certain metabolic pathways that tend to
be affected by NRF2 signaling as a primary or secondary
function, and we evaluate the role of NRF2 in cell survival
based on metabolic rewiring (Fig. 6).
Strategic role of p62 in NRF2 signaling: autophagy and
metabolic rewiring. A considerable body of evidence points
toward a link betweenNRF2 and autophagy, which represents
a conserved strategy to overcome starvation and nutrient
deprivation (162, 329) by recycling cellular macromolecules
and organelles for essential metabolic substrates (222). Dur-
ing autophagy, p62 functions as a marker of proteins and
organelles that are targeted for degradation by the autopha-
gosome. The NRF2 signaling pathway is activated by p62
through the noncanonical mechanism connecting NRF2 to a
spectrum of conditions related to starvation.
In HCC, Parkin-induced autophagy promotes p62 phos-
phorylation on Ser349 by a mechanistic (or mammalian)
target of rapamycin complex 1 (mTORC1), leading to a
concomitant rise in NRF2 protein expression (106). In fact,
p62 binds to the STGE motif of KEAP1 with low affinity,
which increases when p62 is phosphorylated. Hence, phos-
phorylation of p62 effectively induces NRF2 expression
during autophagy (146). The p62-dependent NRF2 activation
also occurs in a carfilzomib- (proteasome inhibitor) resistant
model of multiple myeloma (228).
Other reports contradict the induction of NRF2 in autop-
hagy by p62. A Crispr-based screen focused on finding novel
negative regulators of NRF2 signaling (133) also identified
a number of autophagy-related genes in human kidney HK2
cells. However, subsequent functional analyses demon-
strated that changes in the phosphorylation of p-p62 do not
necessarily induce NRF2 in HK2 cells, indicating that the
autophagy-NRF2 loop can proceed in a p62-independent
manner. In addition, the p62-NRF2 axis is not activated in a
TCS2-deficient kidney cancer model, where upregulated
levels of p62 do not activate NRF2 (153). Thus, NRF2
function in autophagy requires tissue- and context-specific
evaluation. On the other hand, in Atg7-deficient mice, NRF2
activation remains p62 dependent and enhances cellular
growth of HCC in 3D cultures (107).
The p62-NRF2 axis also interacts with signaling pathways
through other pathways besides mTORC1. In HCC, H2O2 and
hypoxia-induced ROS accumulation and NRF2 activation are
p62 dependent (317). In this case, p62 is activated by phos-
phorylation at S28 by ketohexokinase-A (KHK-A), a splice
isoform of phosphofructokinase that possesses protein kinase
activity and KHK-A activation depends on AMPK activation
(317). These changes collectively lead to NRF2-mediated
gene expression and contribute to the development of HCC in
xenograft animals (317). AMPK, a well-known energy
10 SMOLKOVA´ ET AL.
sensor, can also influence NRF2 activity in breast cancer
directly, as AMPK phosphorylates NRF2 and facilitates its
nuclear accumulation (120). In MCF-7 and T47D breast
cancer cells, AMPK activity, induced by glucose deprivation
during nutrient starvation, is necessary for the expression of
NRF2-driven genes (294). In addition, in breast cancer, a
positive feedback loop between p62 and NRF2 has been
demonstrated. The S349 residue of p62 can be phosphory-
lated by class III PtdIns3 lipid kinase (VPS34), whereas
VPS34 induces NRF2-dependent expression of p62 and in-
duces the noncanonical activation of NRF2 (117). Moreover,
VPS34 promotes PKCd-dependent phosphorylation of p62,
also on S349, that not only strengthens the interaction be-
tween NRF2 and p62 in response to caspase inhibitor treat-
ment but also activates downstream signaling pathways
leading to tumor formation, including the MEK/ERK path-
way (117).
In terms of generic carbon rewiring for energymetabolism,
HCC expressing pS349–p62, reprogram both glucose and
glutamine metabolism, marked by the induction of the glu-
curonate pathway and glutamine-derived glutathione syn-
thesis in an NRF2-dependent manner (242). The resulting
increase in glutathione levels is vital to support cancer growth
and chemoresistance. Activation of NRF2 is also critical for
the survival of breast cancer cells in glucose-deprived con-
ditions, as NRF2 induction protected cells from autophagy
and oxidative stress (294). Under glucose-free conditions,
NRF2 enhances cellular survival in a p62-independent fash-
ion (248). The authors suggest that the mechanism is initiated
by ATP deficiency followed by increases in the levels of
NQO1 (248). In accordance with this suggestion, reduced
ATP induces NRF2 activity, causing an alteration in redox
balance, as recently described in lung carcinoma cells (248).
To summarize, a substantial body of evidence supports the
notion that NRF2 can be upregulated by p62, which connects
NRF2 signaling to various means of signal transduction, such
as AMPK and mTORC1. Consequently, NRF2 induction
supports growth in a spectrum of cancer types.
NRF2 regulated ferroptosis and metabolic rewiring through
SLC7A11 expression. Ferroptosis is a form of programmed
cell death that is dependent on iron and independent of
caspases, which is induced specifically by oxidative stress
(55). In principle, inhibition of SLC7A11, depletion of in-
tracellular cysteine and glutathione, and lipid peroxidation
suppress GPX4 activity and initiate ferroptosis. NRF2 reg-
ulates the expression of genes involved in the prevention of
ferroptosis, including iron metabolism, NADPH synthesis,
glutathione reduction, and nonessential amino acid inter-
conversion. The SLC7A11 gene codes for xCT protein, a
subunit of a membrane-localized cystine-glutamate anti-
porter (Xc-), which imports a cysteine dimer (cystine) in
exchange for glutamate. SLC7A11 is a direct target of NRF2,
activating transcription factor 4 (ATF4) (286), and ATF3
(298) and is also a prominent target of NRF2 signaling and
ferroptosis in a number of malignancies.
Consistent evidence demonstrates that the NRF2 tran-
scriptional response, involving the expression of SLC7A11
and xCT, is protective against ferroptosis. This implies that
NRF2-dependent transcription programs lead to escape from
FIG. 6. The role of NRF2 in regulation of cancer cell metabolism. NRF2, activated through canonical or noncanonical
pathways, regulates carbon utilization. Glycolytic flux at the level of G6P is driven toward UDP-Glc and glucoronate
synthesis, as well as toward the PPP cycle, to support the synthesis of ribose and NADPH. Glycolytic flux supports Ser and
Gly synthesis by upregulating PHGDH. Glutathione synthesis is supported by cystine import and glycine synthesis. Cystine
import is connected to glutamate export by Xc- transporter. Fatty acid synthesis and fatty acid oxidation (b-ox) are both
regulated by NRF2. NRF2 also regulates synthesis of polyamines by regulation of MAT2A expression. Pathways upre-
gulated by NRF2 signaling are designated by red arrows. G6P, glucose-6-phosphate; Gly, glycine; PPP, pentose-phosphate
pathway; Ser, serine; UDP-Glc, UDP-glucose. Color images are available online.
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ferroptosis and, in turn, support cell growth. xCT is induced
by H2O2 and NRF2 activation in MCF7 breast cancer cells,
with a concomitant increase in GSH synthesis (82). Also, in
KrasG12D, TP53-/- lung adenocarcinoma cells, the expression
of the KEAP1 LOF mutant induces SLC7A11, which boosts
GSH and reduces ROS levels (247). Moreover, the repression
of xCT impairs colony formation in Ras-transformed cell
models (169). As a result, xCT induction due to NRF2 sig-
naling confers a refractory phenotype in response to the
ferroptosis-inducing agents, erastin or RSL3, in glioma cell
models (62). Further, NRF2 expression coincides with worse
clinical outcome in glioma patients. Recent evidence also
indicates that depletion of ovarian tumor family member
deubiquitinase (OTUB1) (174) or the inactivation of breast
cancer type 1 susceptibility protein (BRCA1) associated
protein 1 (BAP1) tumor suppressor in breast cancer (338)
leads to induction of xCT in an NRF2/hypoxia-inducible
factor 1a (HIF1a)-dependent fashion, which protects cancer
cells from ferroptosis.
It should be noted that a high level of NRF2 accumulation,
which is achieved by the functional impairment of KEAP1 or
NRF2 hyperactivation, combined with sustained oncogenic
signaling, allows NRF2 to modulate metabolism under
pathological conditions. NRF2 redirects glucose and gluta-
mine into anabolic pathways in metabolic reprogramming
(197). In addition, xCT alters cellular glucose and glutamine
utilization to promote cell survival (Fig. 7). The tendency of
cells to prefer glucose and glycolysis in response to xCT
expression level was demonstrated in several cell models
(114). The knockdown of SLC7A11 rescues viability in
glucose-free conditions. Inhibition of xCT in nonsmall lung
cancer cells improves survival in glucose-free medium, when
bioenergetics rely primarily on mitochondrial OXPHOS
through glutamine oxidation (114). Increased xCT expression
sensitizes breast cancer cells to glucose, but not glutamine
withdrawal (262). Thus, the export glutamate via the Xc-
system due to the expression of SLC7A11 maintains glucose
addiction for survival.
Comparing low- and high-expressing SLC7A11 cell lines
revealed that OXPHOS-related gene expression negatively
correlates with the expression level of SLC7A11 in breast
cancer. In turn, xCT expression improved GSH levels and
ROS homeostasis, while diminishing the ability of breast
cancer cells to utilize glutamine instead of glucose (262).
FIG. 7. NRF2 regulates metabolism by
expression of SLC7A11. SLC7A11 is a
prominent target of NRF2 signaling in can-
cer cells. Upregulation of NRF2 results in
expression of Xc
-, an antiporter importing
cystine, which results in enhanced antioxi-
dant defense by GSH synthesis. Glutamate is
exported in exchange for cystine, which
compromises glutaminolytic flux. A subset
of cancer cells are able to support the TCA
cycle (A), whereas another subset of cancer
cells are dependent on glutaminolysis and
2OG anaplerosis, because they are unable to
supply the TCA cycle from glycolysis (B).
Glutamine auxotrophs are, therefore, sus-
ceptible to glutaminolysis inhibitors, such as
CB839, when NRF2 signaling is upregu-
lated. GSH, reduced glutathione; TCA, tri-
carboxylic acid cycle. Color images are
available online.
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A study that grouped breast cancer cell lines based on the
ability to proliferate in glutamine-free conditions revealed
that cells overexpressing SLC7A11 are sensitive to glutamine
withdrawal, as glutamate is excessively exported (284). This
offers the possibility to target both Xc- and glutamine import
in glutamine auxotrophs (284). Another subset of malignan-
cies is unable to upregulate glycolysis to compensate for loss
of glutamine as a carbon source (Fig. 7). In accordance with
these data, studies using KRASG12V, TP53-/- cell models of
lung adenocarcinoma expressing an LOF form of KEAP1,
demonstrate the vulnerability of xCT overexpressing cells to
glutamine withdrawal. These cell models also have an in-
creased sensitivity to glutaminase 1 inhibitor CB-839 (247),
which can be overcome by pretreatment with erastin or
knockdown of SLC7A11. In this case, active export of gluta-
mate limits mitochondrial anaplerosis, which, in turn, sensi-
tizes the cells to CB-839 treatment. Thus, a combination of
KI696, a compound inhibitingKEAP1-NRF2 interaction,with
CB-839 is another plausible strategy to target NRF2 over-
expressing cancers. In support of this therapeutic approach,
another line of evidence also documents enhanced glutamine
dependence due to KEAP1-NRF2 in the KRAS/LKB1/
KEAP1 transformed lung cancer (72). Further, a recent study
(157) also demonstrated that the NRF2-mediated induction of
the Xc- system limits intracellular glutamate content that,
consequently, leads to an external dependency on nonessential
amino acids (serine, glycine, and asparagine) in cancer cells,
rendering cells metabolically inflexible. The antioxidant ca-
pacity of cancer cells, indeed, shows an inverse correlation
with nonessential amino acids synthesizing capacity. As cells
are reliant on nonessential amino acids, a diet that avoids these
amino acids can limit cancer cell proliferation.
A recent publication (126) suggested that the NRF2-
mediated accumulation of cysteine in nonsmall cell lung
cancer may induce metabolic liability. The mechanism
of metabolic liability is that cystein in superphysiological
concentrations becomes a substrate for cysteine dioxygen-
ase 1 (CDO1), creating cysteine sulfinic acid that apparently
hampers cellular proliferation. From a broader perspective,
this metabolic inflexibility can be exploited in combating
nonsmall cell lung cancer.
NRF2 interference with hypoxia signaling and neovascu-
larization. Hypoxia, a common feature of the tumor mi-
croenvironment, leads to the stabilization of HIF1a, which
modulates cellular metabolism as an adaptive response (252).
HIF1a expression initiates transcriptional programs that lead
to survival and overcome hypoxia by inducing angiogenesis,
glycolysis, and a decrease in pyruvate oxidation in mito-
chondria. NRF2 activation supports glycolysis by promoting
the stabilization of transcription factor BTB and CNC ho-
mology 1 (Bach1) that supports the activity of hexokinase
(168, 309). This effect of NRF2 is mediated by induction of
HMOX1, which catabolizes heme, the main inhibitor of
Bach1. Both NRF2 and HIF1a are critical factors for sensing
O2 and are dependent on each other when responding to ox-
ygen tension changes or ROS production. Of note, HIF1a is
probably a target of NRF2; an ARE was identified in the
HIF1a promoter (152). Strikingly, NRF2 silencing sup-
presses HIF1a accumulation in breast cancer cells under
hypoxic conditions. Thus, HIF1a-mediated metabolic adap-
tations, including the activation of glycolysis and PPP, are
inhibited. Inhibition of metabolic adaptations eventually
impairs the viability of NRF2-silenced cancer cells in a
hypoxic environment (159). Further evidence suggests that
NRF2 is induced in hypoxia due to elevated ROS (250) and
the subsequent induction of GCLC and GSH synthesis.
Hence, chemoresistance is promoted (11). A recent in vitro
study showed that both NRF2 and HIF1a are upregulated in
MCF-7 and MDA-MB-231 breast cancer cells, compared
with MCF-10A cells (a benign breast epithelial cell line).
These results suggest that NRF2 and HIF1a simultaneously
contribute to cell proliferation and tumor formation in breast
cancer (333). Further, NRF2 can promote glycolysis in breast
cancer cells in cooperation with HIF1a (333).
In addition to the well-known angiogenic role of HIF1a to
overcome hypoxia, the NRF2 pathway also contributes to
neovascularization in cancer models. The induction of NRF2
in endothelial cells promotes cell motility and angiogenesis
(102). In addition, the expression of platelet derived growth
factor and VEGF, strategic angiogenesis inductors, are reg-
ulated by HIF1a and NRF2, as demonstrated in a prostate
cancer model (323). Moreover, loss of NRF2 inhibited HIF1a
accumulation and VEGF induction, resulting in reduced an-
giogenesis in colorectal carcinoma cells (140); this effect was
mediated by the induction of HIF1a hydroxylation in hypoxia.
NRF2 in the regulation of PPP flux. PPP is upregulated in
many types of tumors, including breast cancer where PPP
promotes proliferation, differentiation, and survival. Breast
cancer cells either overexpress NRF2 or cells, in which
KEAP1 is silenced, or upregulate G6pd (318, 334). This ob-
servation appears to be generalizable; the activities of G6pd
and transketolase (TKT), key PPP enzymes, are commonly
increased in cancer cells (318). Oxidative PPP converts G6P,
a glycolytic intermediate, into ribulose-5-phosphate and
generates NADPH, which is used for GSH regeneration, de-
toxification, and biosynthesis of lipids. NRF2 directly acti-
vates five genes involved in PPP and NADPH production
pathways, including G6pd, PGD, TKT, transaldolase 1, and
ME1, through binding to AREs (306). The G6pd target for
NRF2 is a critical enzyme in the PPP, catalyzing the rate-
limiting step that produces NADPH (24).
A recent report showed that NRF2 contributes to the meta-
static ability of basal type breast cancer cells through the G6pd/
HIF-1a/Notch1 signaling axis. NRF2-dependent G6pd/HIF-1a
activation elicits Notch1 signaling by upregulating Jagged1
and Hes1, and, thereby, promoting epithelial-mesenchymal
transition (EMT) in breast cancer cells (334). In addition, a
clinical study showed that PPP-related proteins are differen-
tially expressed according to the molecular subtype of breast
cancer; in particular, G6pd and 6-phosphogluconolactone are
highly expressed in HER2-type breast cancer (35). Thus, un-
derstanding the role of this pathway in breast cancers, includ-
ing the effects of targeting this pathway, is needed to clarify the
clinical implications of PPP in breast cancers. Benito et al. (19)
demonstrated critical rewiring of glucose flux due to theNRF2-
inducedG6pd and TKT expression; the changes in glucose flux
included increased ribose and NADPH synthesis, which are
associated with poor outcomes in breast cancer patients.
However, in contradiction to previous studies, the NRF2 level
was downregulated in all types of breast cancers in the TCGA
dataset, suggesting a possible role of NRF2 as a tumor sup-
pressor in breast cancer (35). It is also possible that the result of
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the RNA sequencing may not reflect the actual activity of
NRF2 in cells due to post-translational regulation by ubiqui-
tination and degradation (35).
Methionine adenosyltransferase 2A. Polyamines, such
as putrescine, spermine, and spermidine, have unknown bi-
ological function and accumulate in cancer cells, resulting in
increased proliferation. Upregulated enzymes of polyamine
pathways have been implicated in several cancer types (26).
Methionine adenosyltransferase (MAT) is an essential cel-
lular enzyme that is ubiquitously expressed in mammalian
cells;MAT catalyzes the formation of S-adenosylmethionine,
the principal biological methyl donor and the ultimate source
of the propylamine moiety used in polyamine biosynthesis
(189). Altered expression of methionine adenosyltransferase
2A (MAT2A), an isoform of MAT, in tamoxifen-resistant
(TAMR) breast cancer and the role of MAT2A in tumor
growth and chemoresistance have been described in the
context of NRF2 regulation. MAT2A expression is upregu-
lated in TAMR-MCF-7 cells compared with control MCF-7
cells. Moreover, MAT2A expression, associated with altered
NRF2 expression levels, is more frequent in TAM-resistant
human breast cancer tissues than in TAM-responsive cases
(216). This genetic correlation between MAT and NRF2 has
been partially clarified; the promoter of MAT2A contains
several potential binding sites for transcription factors, in-
cluding c-Myb, NRF2, NF-jB, and AP-1 (322), suggesting
that NRF2 could be vital in regulating the expression of
MAT2A.MAT2A immunoreactivity is significantly higher in
TAMR cases of human breast cancer compared with TAM-
sensitive cases, and it is associated with the overexpression of
NRF2 (215). However, whether this association is direct or
acts via another intermediate pathway that links MAT2A and
NRF2 is unclear. NF-jB also regulates MAT2A gene tran-
scription, suggesting an underlying mechanism of enhanced
NF-jB activity related tomiR-146b downregulation, which is
associated with NRF2 expression, in TAMR breast cancer
(104). Therefore, decreasedmiR-146b andMAT2A induction
could be a new phenotype contributing to the growth of breast
cancer cells and tamoxifen resistance in breast cancer cells.
NRF2 in the regulation of stemness,
EMT, and metastasis
EMT is a trans-differentiation process that enables cell
migration. EMT constitutes the initial step of metastatic
progression. During EMT, typical markers of the mesen-
chymal phenotype, such as Vimentin, N-cadherin, Snail,
Slug, Twist, and ZEB1, are increased, whereas epithelial
markers, such as cell adhesion markers (E-cadherin, MUC-1,
and laminin) are lost. Mesenchymal cells also merge phe-
notypically with circulating tumor cells (CTCs), which are
considered a negative prognostic marker of cancer (326).
Isolated CTCs usually form clusters, which is a feature of the
mesenchymal phenotype (327). In addition, CTCs express
the stem cell marker, CD133 (9). On the other hand, mes-
enchymal–epithelial transition (MET) is the reverse process
of EMT by which cells initiate in situ metastases.
Although research in EMT advanced in recent years, there
is persistent controversy regarding the existence of EMT/
MET phenotype in CSCs, which are also implicated in tumor
maintenance and metastasis. EMT mediators can lead to
increments of the CSC phenotype (249). CSC are defined
by specific expression of cell surface markers (CD24low,
CD44high), the expression of aldehyde-dehydrogenase
1 (ALDH1), and low proliferation rate (50). The typical
experimental in vitro models, leading to CSCs enrichment,
are ‘‘spheroids’’ cultivated from cell cultures. These spher-
oids are also used for xenograft studies, due to the improved
engraftment compared with conventional 2D cell cultures
(129). The overlap of CSC issues with the EMT phenomenon
is further underlined by the existence of defined epithelial-
like and mesenchymal-like CSCs classes (273). Moreover, a
hybrid epithelial/mesenchymal (E/M) state of cells has been
described recently as the mixed phenotype preceding full
mesenchymal state (151). Nevertheless, studying EMT and
CSCs in vivo is rather challenging, given that the phenome-
non is typically difficult to capture in real-time, due to the
rapid exchange of the markers associated with EMT/MET
once the transition is completed.
Information regarding the involvement of NRF2 in EMT,
MET, and CSC phenotypes is rather ambiguous, due to the
variety of experimental models. NRF2 induction most likely
promotes spheroid formation and the CSC phenotype. A study
by Luo et al. (180) demonstrated that transition fromCD24low
CD44high CSCs (mesenchymal-like stem cells) into ALDH+
breast cancer CSCs (epithelial-like stem cells) is accompanied
by theNRF2-dependent gene expression signature in response
to metabolic perturbation such as 2-deoxyglucose treatment
(180). Inhibition of NRF2 and the antioxidant system (Txns
and GSH) inhibits sphere formation and cancer growth in vivo
(180). In breast cancer cells, the expression of CD44 coincides
with higher NRF2 expression andmarkers of CSC-like cancer
cells (239, 240). The induction of NRF2 in CD44+ cells is de-
pendent on the noncanonical activation of NRF2 through p62,
and NRF2 induction facilitates spheroid formation and induces
chemoresistance to 5-fluorouracil and doxorubicin (239, 240).
Formation of spheroids and xenografts is suppressed af-
ter NRF2 silencing in CD44high cells in the same studies
(239, 240). Moreover, Kipp et al. (143) used a remarkable
fluorescence-based in vitro model of monitoring NRF2 ex-
pression to demonstrate that NRF2 is clearly induced during
spheroid formation. NRF2 induction by the Txnrd1 inhibitor,
auranofin, promotes spheroid growth, evidenced by prolif-
eration and differentiation markers, rather than the quiescent
(CSC-like) phenotype. In line with this, Kova´cs et al. (149)
showed that the 4-hydroxynonenal content in breast cancer
tissue negatively correlated with the proliferation of cancer
cells. On the contrary, another point of view was provided in
a study by Bocci (21) showing that the knockdown of NRF2
induces mesenchymal markers and the transition from hybrid
E/M to the mesenchymal phenotype. NRF2 expression in
TCGA datasets also corresponds with the expression of E/M
markers (high ZEB1, high miR-200) and elevated NRF2 ex-
pression correlates with a worse prognosis of breast cancer (21).
Another aspect of CSCs is cell migration and invasion,
which can also be supported by NRF2 signaling. In cell
models of breast cancer, NRF2 overexpression or KEAP1
knockdown promotes cell migration (assessed by wound
healing assay) and invasion (transwell invasion assay)
through G6pd and possibly Notch1 induction (334). More-
over, the CD24-CD44+ mesenchymal subpopulation of sev-
eral human breast cancer cell lines is characterized by
upregulated TrkB-AKT signaling that suppresses KEAP1
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Table 2. Interactions Between the NRF2-KEAP1 System and Cytostatic Drugs
Drug Effect Cancer Reference
Platinium compounds
Cysplatin NRF2 overexpression confers resistance to cisplatin Cervix cancer (303)
Lung cancer (20, 137, 265,
283, 299)
Ovarian cancer (15, 34, 275)
Laryngeal cancer (345)
Bladder cancer (43, 91)
Head and neck tumors (230)
NRF2 overexpression protects against Cysplatin
nephrotoxicity
N/A (302)
NRF2 overexpression protects against Cysplatin
ototoxicity
N/A (64)
Oxaliplatin High NRF2 expression leads to resistance to Cysplatin Colon cancer (217, 305)
NRF2 knockout protects against Oxaliplatin-induced
peripheral neuropathy
N/A (325)
Carboplatin NRF2 upregulation protects against Carboplatin
treatment
Epithelial ovarian cancer (147)
Nucleotide analogs
Cordycepin Cordycepin induces NRF2 that protects against
radiation ulcer
N/A (307)
Cordycepin induces NRF2 Breast cancer (56)
Cytarabine NRF2 overexpression confers Cytarabine resistance Myelosdysplasy (171)
5-fluorouracil Vitamin D in combination with 5-fluorouracil protects
against hepatocellular carcinoma
Hepatocellular carcinoma (1, 255)
NRF2 overexpression leads to 5-fluorouracil resistance Colorectal cancer (125, 173)
NRF2 downregulation or Keap1 loss-of-function
enhances the effect of 5-fluorouracil
Cholangiocarcinoma (244, 256)
NRF2 overexpression leads to 5-fluorouracil resistance Gastric cancer (103)
NRF2 activation supports cell proliferation under
5-fluorouracil treatment
Pancreatic cancer (172)
NRF2 induction protects against 5-fluorouracil-induced
myelosuppression
N/A (206)
Gemcitabine Reduction of NRF2 sensitizes pancreatic cancer cells to
gemcitabine
Pancreatic cancer (57, 121, 316)
Gemcitabine effects are enhanced by the downregula-
tion of NRF2
Cholangiocarcinoma (244)
Monoclonal antibodies
Bevacizumab NRF2 overexpression confers resistance to VEGF
inhibition
Glioblastoma (319)
Vincalkaloids
Vinorelbine NRF2 overexpression confers Vinorelbine resistance Lung cancer (314)
Vincristine NRF2 protects against Vincristine-induced neuropathic
pain
N/A (342)
Anthracycline drugs
Doxorubicin Doxorubicine decreases NRF2 expression N/A (205)
NRF2 activation confers doxorubicin resistance Ovarian cancer (260)
Tyrosine kinase inhibitors
Lapatinib NRF2 overexpression leads to resistance against
lapatinib
Ovarian cancer (127)
Lapatinib inhibits NRF2 expression N/A (210)
Erlotinib NRF2 overexpression leads to resistance against
erlotinib
Ovarian cancer (127)
Vorinostat in combination with Gefitinib or Erlotinib
suppresses NRF2 expression
Nonsmall-cell lung cancer (160)
Gefitinib Vorinostat in combination with Gefitinib or Erlotinib
suppresses NRF2 expression
Nonsmall-cell lung cancer (160)
Topoisomerase inhibitors
Camptotechin Camptotechin suppresses NRF2 expression Hepatocellular carcinoma (29)
(continued)
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expression (138). In agreement with that, NRF2 accumula-
tion in the nucleus can be prevented by the presence of
E-cadherin, which is present in epithelial cells, but not in
mesenchymal cells (141). The mechanism of this process
requires sequestration of the NRF2/KEAP1 complex in the
proximity of the plasma membrane and involves the inter-
action of NRF2 with b-catenin (141).
Of note, NRF2 is involved in the crosstalk between asso-
ciated cell species and tumor bulk cells in HCC and PDAC
(63). Lactate produced and secreted by cancer cells into the
environment and elevated ROS levels induce NRF2 in tumor-
associated macrophages, converting them to theM2 (CD163+)
polarized phenotype. NRF2 in M2 macrophages was essential
for the induction of migration and expression of EMTmarkers
in tumor bulk cells via VEGF signaling, which also induces
NRF2 levels.
The role of NRF2 in DNA repair
As previously mentioned, the induction of NQO1 by NRF2
prevents DNA damage (267, 270). NRF2 is responsible for
DNA protection at multiple levels and for different kinds of
DNA damage inducers, such as irradiation or chemical ex-
posure. Reduction of NRF2 levels sensitizes cells to irradi-
ation, a process involving the decreased ability to repair DNA
via homologous recombination, by inhibiting RAD51 levels
Table 2. (Continued)
Drug Effect Cancer Reference
Alkylating agents
Cyclophosphamide NRF2 activation counteracts Cyclophosphamide-
induced myelosuppression
N/A (221)
Themozolomide NRF2 overexpression confers resistance to Themozo-
lomide
Glioma (229)
Themozolomide and radiation therapy induces NRF2
expression
Glioblastoma (39)
Proteasome inhibitors
Bortezomib NRF2 overexpression confers protection against
Bortezomib treatment
Neuroblastoma (69, 70)
Bortezomib induces NRF2 expression Multiple myeloma (17)
NRF2 overexpression protects against Bortezomib
treatment
Mantle cell lymphoma (308)
Nuclear receptor modulators
Tamoxifen NRF2 overexpression contributes to Tamoxifen resis-
tance
Breast cancer (18, 215)
Retinoic acid Retinoic acid suppresses NRF2 Breast cancer (304)
Other cytostatic drugs
Vorinostat Vorinostat in combination with Gefitinib or Erlotinib
suppresses NRF2 expression
Nonsmall-cell lung cancer (160)
Arsenic trioxide Arsenic trioxide induces NRF2 Acute promyelocytic
leukemia
(199)
Radiotherapy
NRF2 overexpression protects against radiotherapy Ovarian cancer (291)
NRF2 overexpression protects against radiotherapy Esophageal squamous
cancer
(132)
Gain-of-function NRF2 mutation confers malignant
potential
Esophageal squamous
cancer
(257)
NRF2 activation supports cell proliferation under
radiotherapy
Pancreatic cancer (172)
Studies with no drug defined
Not defined NRF2 overexpression confers resistance to chemother-
apy
Hepatobiliary cancer (136)
NRF2 overexpression confers resistance to chemora-
diotherapy
Esophageal squamous
cell cancer
(336)
NRF2 inhibition confers sensitivity to chemotherapy Cholangiocarcinoma (272)
NRF2 expression shows negative correlation with
neoadjuvant chemotherapy success
Breast cancer (231)
NRF2 activation protects against chemotherapy Colorectal cancer (241)
NRF2 downregulation increases the efficacy of che-
motherapy
Cervical cancer (182)
NRF2 protects against chemotherapy Leukemia (237)
High NRF2 expression confers chemoresistance Endometrial cancer (116)
NRF2 downregulation is vital for chemotherapy success Chronic lymphocytic
leukemia
(312)
NRF2 expression is associated with chemotherapy
resistance
Ovarian cancer (97)
N/A, not applicable; VEGF, vascular endothelial growth factor.
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(112). The study by Jayakumar (112) also indicates addi-
tional targets containing ARE sequences that are active in
DNA repair, including possible targets of NRF2. NRF2 also
regulates expression of ATM and ATR after cysplatin ex-
posure in an ovarian cancer model via stress-induced kinases
specific to the DNA damage response (267). In addition,
synthetic tripertenoids activate NRF2 and protect cells from
radiation damage (60, 139). In this case, the role of NRF is
controversial (285) in terms of cancer progression, since
NRF2 might prevent DNA damage and cancer progression.
The role of NRF2 in aging and lifespan regulation
In Drosophila, NRF2 expression extends the lifespan and
induces tolerance to paraquat treatment (285).A straightforward
study (164) investigated NRF2 signaling on naked mole rats
and stratified NRF2 expression according to the maximum
species lifespan potential (MSLP). The study revealed that
NRF2 activity and downstream targets exhibit positive cor-
relation with MSLP, due to the diminished activity or ex-
pression of canonical and noncanonical negative regulators.
In addition, a spectrum of NRF2 target genes and proteins
were recently identified in a high-throughput study; these
NRF targets were differentially regulated in the long-lived
naked mole rat and the short-lived guinea pig, its close rela-
tive (96). Nevertheless, there are contradicting reports con-
cerning the role of NRF2 in longevity. For example, in Nqo1-
deficient mice, the lifespan is improved under caloric re-
striction, but not under ad libitum conditions (53). Taken
together, the lifespan-prolonging effect of NRF2 has not been
conclusively demonstrated.
Future Prospects
NRF2 is a vital component of the cellular machinery that
conserves cellular redox balance through the expression of
antioxidant proteins. Reactive oxygen and nitrogen species
have a dual nature in carcinogenesis. On one hand, enhanced
reactive species production increases the risk for neoplastic
diseases by increasing the mutation rate and, hence, in-
creasing the chance of transformation (158). On the other
hand, in cancer cells, reactive species negatively regulate
cancer cell survival (149, 158). It is also of note that although
low NRF2 expression is associated with senescence, the in-
duction of NRF2 expression is apparently associated with
Table 3. Values for the Survival Curve on Figure 4
Number at risk (months)
Bladder carcinoma
HR= 0.69
p= 0.021
0 50 100 150
Low expression 115 16 3 2
High expression 289 50 9 1
Cervical
Cervical squamous cell carcinoma
HR= 0.53
p= 0.25
0 50 100 150 200
Low expression 214 37 9 4 1
High expression 90 24 11 3 1
Stomach adenocarcinoma
HR= 0.66
p= 0.05
0 20 40 60 80
Low expression 277 96 27 10 3
High expression 94 38 8 5 1
Kidney renal clear cell carcinoma
HR= 0.48
p= 1.6 · 10–6
0 50 100 150
Low expression 159 46 6 0
High expression 371 160 34 1
Lung squamous cell carcinoma
HR= 0.68
p= 0.0087
0 50 100 150
Low expression 309 52 16 2
High expression 186 53 11 3
Sarcoma
HR= 0.52
p= 0.0021
0 50 100 150
Low expression 64 14 4 2
High expression 195 59 12 3
Kidney renal papillary cell carcinoma
HR= 1.73
p= 0.07
0 50 100 150 200
Low expression 155 38 9 1 0
High expression 132 35 3 0 0
Liver hepatocellular carcinoma
HR= 1.48
p= 0.053
0 20 40 60 80
Low expression 114 54 27 17 8
High expression 256 128 57 25 11
Pancreatic ductal adenocarcinoma
HR= 1.56
p= 0.45
0 20 40 60 80
Low expression 127 46 15 8 1
High expression 50 12 2 0 0
Thymoma
HR= 4.27
p= 0.032
0 50 100 150
Low expression 87 40 11 2
High expression 31 10 0 0
(continued)
Table 3. (Continued)
Number at risk (months)
Thyroid carcinoma
HR = 1.93
p = 0.19
0 50 100 150
Low expression 365 90 22 3
High expression 137 38 12 4
Uterine corpus endometrial carcinoma
HR = 1.37
p = 0.16
0 50 100 150 200
Low expression 377 115 17 3 1
High expression 165 32 3 0 0
HR, hazard ratio.
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cancer cell survival (5, 46, 68, 149, 158, 290, 343). This dual
nature of free radicals confers an interesting, ambiguous
nature to NRF2 in cancer biology. The pro- or antineoplastic
effects of NRF2 are context dependent; thus, the effects of
NRF2 depend on the nature and molecular characteristics of
the cancer in question. Large-scale studies to carefully
evaluate cancer subtypes, where NRF2 signaling can be tar-
geted, should be a focus for the future.
NRF2 promotes several enabling cancer hallmarks, such as
metabolism, CSC characteristics, tumor aggressiveness, in-
vasion, and metastasis formation. The role of NRF2 in reg-
ulating cancer cell stemness and EMT seems to be a central
feature in defining the role of NRF2 in regulating metastasis
and progression among the neoplastic processes. The level of
NRF2 activity is apparently a switch in metabolism and
ferroptosis that enables cancer cells to mobilize nutrients to
support growth, enable metabolic flexibility, and avoid cell
death. The bulk of cancer cells are sensitive to chemotherapy
and are rather reliant on Warburg metabolism, whereas stem
cells are metabolically flexible and resistant to chemotherapy
(66, 214). Therefore, from a translational point of view, fine-
tuning NRF2 activity may help in reprogramming CSCs to
become more sensitive to chemotherapy (126). Under-
standing the complex metabolic rearrangements behind
NRF2 activation will be crucial in understanding the poten-
tial interference of ROS signaling and metabolic rewiring in
cancer and other pathologies.
Immune destruction is a major pathway to eliminate cancer
cells, involving the production of reactive species. It remains
an open question of whether NRF2 is involved in protecting
against immune destruction. Logically, the NRF2-driven
antioxidant response is probably protective against immune
cell-derived free radicals and, therefore, may be pro-
neoplastic. Further, NRF2 activity modulates the function of
antigen-presenting dendritic cells and T cells (165, 330),
implying a modality to improve anticancer immune response.
There are only a few papers on the interactions between the
NRF2 pathway and chemotherapy regimens (12) (Table 2);
understanding these interactions can help identify the best
therapeutic window for NRF2 activators or inhibitors. Most
likely, the picture will be very complex, as some chemother-
apeutic agents produce superoxide [e.g., doxorubicin (10, 211,
212)], which interferes with the NRF2 system. Further, the
scavenging of free radicals produced by chemotherapeutic
drugs is controversial (176). The modulation of NRF2 tone
will likely impact the sensitivity of tumors to chemotherapy.
The exploitation of the NRF2 pathway clearly holds
promise in the clinical setting. Nevertheless, substantial
studies are needed to sharply pinpoint the diseases, patient
subgroups, and therapeutic schemes where NR2-directed
therapies will be beneficial.
Acknowledgment
The authors are grateful to Dr. Karen Uray (University of
Debrecen, Department of Medical Chemistry) for the critical
revision of the text.
Funding Information
This work was supported by the NKFIH (K123975,
PD124110, FK128387, GINOP-2.3.2-15-2016-00006) to
P.B., the Hungarian Academy of Sciences (NKM-26/2019) to
P.B., the Czech Health Research Council project number
NV19-01-00101 to K.S., and institutional funding of IPHYS
CAS number RVO67985823. E.M. was supported by the
Bolyai fellowship from the Hungarian Academy of Sciences.
The research was financed by the Higher Education Institu-
tional Excellence Programme (NKFIH-1150-6/2019) of the
Ministry of Innovation and Technology in Hungary, within
the framework of the Biotechnology thematic programme of
the University of Debrecen. E.M. is supported by the U´NKP-
19-4-DE-79 New National Excellence Program of the Min-
istry of Human Capacities.
References
1. A RE, El-Mesery M, El-Karef A, and Eissa LA. Vitamin
D potentiates anti-tumor activity of 5-fluorouracil via
modulating caspase-3 and TGF-beta1 expression in he-
patocellular carcinoma-induced in rats. Can J Physiol
Pharmacol 96: 1218–1225, 2018.
2. Abbas K, Breton J, Planson AG, Bouton C, Bignon J,
Seguin C, Riquier S, Toledano MB, and Drapier JC. Nitric
oxide activates an Nrf2/sulfiredoxin antioxidant pathway
in macrophages. Free Radic Biol Med 51: 107–114, 2011.
3. Abu-Alainin W, Gana T, Liloglou T, Olayanju A, Barrera
LN, Ferguson R, Campbell F, Andrews T, Goldring C,
Kitteringham N, Park BK, Nedjadi T, Schmid MC,
Slupsky JR, Greenhalf W, Neoptolemos JP, and Costello
E. UHRF1 regulation of the Keap1-Nrf2 pathway in
pancreatic cancer contributes to oncogenesis. J Pathol
238: 423–433, 2016.
4. Ahmad F, Dixit D, Sharma V, Kumar A, Joshi SD, Sarkar
C, and Sen E. Nrf2-driven TERT regulates pentose
phosphate pathway in glioblastoma. Cell Death Dis 7:
e2213, 2016.
5. Ahn B, Pharaoh G, Premkumar P, Huseman K, Ranjit R,
Kinter M, Szweda L, Kiss T, Fulop G, Tarantini S, Csiszar
A, Ungvari Z, and Van Remmen H. Nrf2 deficiency ex-
acerbates age-related contractile dysfunction and loss of
skeletal muscle mass. Redox Biol 17: 47–58, 2018.
6. Akdemir B, Nakajima Y, Inazawa J, and Inoue J. miR-432
induces NRF2 stabilization by directly targeting KEAP1.
Mol Cancer Res 15: 1570–1578, 2017.
7. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM,
and Cook JL. Nrf2, a Cap’n’Collar transcription factor,
regulates induction of the heme oxygenase-1 gene. J Biol
Chem 274: 26071–26078, 1999.
8. Ali D, Mohammad DK, Mujahed H, Jonson-Videsater
K, Nore B, Paul C, and Lehmann S. Anti-leukaemic ef-
fects induced by APR-246 are dependent on induction
of oxidative stress and the NFE2L2/HMOX1 axis that
can be targeted by PI3K and mTOR inhibitors in acute
myeloid leukaemia cells. Br J Haematol 174: 117–126,
2016.
9. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bit-
ting RL, Turnbull JD, Herold CI, Marcom PK, George DJ,
and Garcia-Blanco MA. Circulating tumor cells from
patients with advanced prostate and breast cancer display
both epithelial and mesenchymal markers. Mol Cancer
Res 9: 997–1007, 2011.
10. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, and
Pacher P. Matrix metalloproteinase activation is an early
event in doxorubicin-induced cardiotoxicity. Oncol Rep
11: 505–508, 2004.
11. Bai X, Chen Y, Hou X, Huang M, and Jin J. Emerging
role of NRF2 in chemoresistance by regulating drug-
18 SMOLKOVA´ ET AL.
metabolizing enzymes and efflux transporters. Drug Me-
tab Rev 48: 541–567, 2016.
12. Bala A and Panditharadyula SS. Role of nuclear factor
erythroid 2-related factor 2 (NRF-2) mediated antioxidant
response on the synergistic antitumor effect of L-arginine
and 5-fluro uracil (5FU) in breast adenocarcinoma. Curr
Pharm Des 25: 1643–1652, 2019.
13. Banerjee P, Basu A, Datta D, Gasser M, Waaga-Gasser
AM, and Pal S. The heme oxygenase-1 protein is over-
expressed in human renal cancer cells following activation
of the Ras-Raf-ERK pathway and mediates anti-apoptotic
signal. J Biol Chem 286: 33580–33590, 2011.
14. Bao L, Wu J, Dodson M, Rojo de la Vega EM, Ning Y,
Zhang Z, Yao M, Zhang DD, Xu C, and Yi X. ABCF2, an
Nrf2 target gene, contributes to cisplatin resistance in
ovarian cancer cells. Mol Carcinog 56: 1543–1553, 2017.
15. Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX, Yao M,
Zhang DD, and Yi XF. Nrf2 induces cisplatin resistance
through activation of autophagy in ovarian carcinoma. Int
J Clin Exp Pathol 7: 1502–1513, 2014.
16. Barbano R, Muscarella LA, Pasculli B, Valori VM, Fon-
tana A, Coco M, la Torre A, Balsamo T, Poeta ML,
Marangi GF, Maiello E, Castelvetere M, Pellegrini F,
Murgo R, Fazio VM, and Parrella P. Aberrant Keap1
methylation in breast cancer and association with clini-
copathological features. Epigenetics 8: 105–112, 2013.
17. Barrera LN, Rushworth SA, Bowles KM, and MacEwan
DJ. Bortezomib induces heme oxygenase-1 expression in
multiple myeloma. Cell Cycle 11: 2248–2252, 2012.
18. Bekele RT, Venkatraman G, Liu RZ, Tang X, Mi S,
Benesch MG, Mackey JR, Godbout R, Curtis JM,
McMullen TP, and Brindley DN. Oxidative stress con-
tributes to the tamoxifen-induced killing of breast cancer
cells: implications for tamoxifen therapy and resistance.
Sci Rep 6: 21164, 2016.
19. Benito A, Polat IH, Noe V, Ciudad CJ, Marin S, and
Cascante M. Glucose-6-phosphate dehydrogenase and
transketolase modulate breast cancer cell metabolic re-
programming and correlate with poor patient outcome.
Oncotarget 8: 106693–106706, 2017.
20. Bialk P, Wang Y, Banas K, and Kmiec EB. Functional
gene knockout of NRF2 increases chemosensitivity of
human lung cancer A549 cells in vitro and in a xenograft
mouse model. Mol Ther Oncolytics 11: 75–89, 2018.
21. Bocci F, Tripathi SC, Vilchez Mercedes SA, George JT,
Casabar JP, Kin Wong P, Hanash SM, Levine H, Onuchic
JN, and Kumar Jolly M. NRF2 activates a partial epithelial-
mesenchymal transition and is maximally present in a hy-
brid epithelial/mesenchymal phenotype. Integr Biol 11:
251–263, 2019.
22. This reference has been deleted.
23. Bollong MJ, Lee G, Coukos JS, Yun H, Zambaldo C,
Chang JW, Chin EN, Ahmad I, Chatterjee AK, Lairson
LL, Schultz PG, and Moellering RE. A metabolite-derived
protein modification integrates glycolysis with KEAP1-
NRF2 signalling. Nature 562: 600–604, 2018.
24. Brewer AC, Mustafi SB, Murray TVA, Rajasekaran NS,
and Benjamin IJ. Reductive stress linked to small HSPs,
G6PD, and Nrf2 pathways in heart disease. Antioxid Re-
dox Signal 18: 1114–1127, 2013.
25. Camp ND, James RG, Dawson DW, Yan F, Davison JM,
Houck SA, Tang X, Zheng N, Major MB, and Moon RT.
Wilms tumor gene on X chromosome (WTX) inhibits
degradation of NRF2 protein through competitive bind-
ing to KEAP1 protein. J Biol Chem 287: 6539–6550,
2012.
26. Casero RA, Murray Stewart T, and Pegg AE. Polyamine
metabolism and cancer: treatments, challenges and op-
portunities. Nat Rev Cancer 18: 681–695, 2018.
27. Chang CW, Chen YS, Tsay YG, Han CL, Chen YJ, Yang
CC, Hung KF, Lin CH, Huang TY, Kao SY, Lee TC, and
Lo JF. ROS-independent ER stress-mediated NRF2 acti-
vation promotes warburg effect to maintain stemness-
associated properties of cancer-initiating cells. Cell Death
Dis 9: 194, 2018.
28. Chen C, Jiang X, Gu S, and Zhang Z. MicroRNA-155
regulates arsenite-induced malignant transformation by
targeting Nrf2-mediated oxidative damage in human
bronchial epithelial cells. Toxicol Lett 278: 38–47, 2017.
29. Chen F, Wang H, Zhu J, Zhao R, Xue P, Zhang Q, Bud
Nelson M, Qu W, Feng B, and Pi J. Camptothecin sup-
presses NRF2-ARE activity and sensitises hepatocellular
carcinoma cells to anticancer drugs. Br J Cancer 117:
1495–1506, 2017.
30. Chen PH, Smith TJ, Wu J, Siesser PF, Bisnett BJ, Khan F,
Hogue M, Soderblom E, Tang F, Marks JR, Major MB,
Swarts BM, Boyce M, and Chi JT. Glycosylation of
KEAP1 links nutrient sensing to redox stress signaling.
EMBO J 36: 2233–2250, 2017.
31. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, and
Zhang DD. Direct interaction between Nrf2 and p21(Cip1/
WAF1) upregulates the Nrf2-mediated antioxidant re-
sponse. Mol Cell 34: 663–673, 2009.
32. Cheng K-C, Lin R-J, Cheng J-Y, Wang S-H, Yu J-C, Wu
J-C, Liang Y-J, Hsu H-M, Yu J, and Yu AL. FAM129B,
an antioxidative protein, reduces chemosensitivity by
competing with Nrf2 for Keap1 binding. EBioMedicine
45: 25–38, 2019.
33. Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera
K, Palm W, Wilson J, Sangar V, Hao Y, Ohlund D,
Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C,
Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H,
Hammell M, Crawford HC, Schmidt EE, Thompson CB,
Pappin DJ, Sonenberg N, and Tuveson DA. NRF2 pro-
motes tumor maintenance by modulating mRNA transla-
tion in pancreatic cancer. Cell 166: 963–976, 2016.
34. Cho JM, Manandhar S, Lee HR, Park HM, and Kwak MK.
Role of the Nrf2-antioxidant system in cytotoxicity me-
diated by anticancer cisplatin: implication to cancer cell
resistance. Cancer Lett 260: 96–108, 2008.
35. Choi J, Kim E-S, and Koo JS. Expression of pentose
phosphate pathway-related proteins in breast cancer. Dis
Markers 2018: 9369358, 2018.
36. This reference has been deleted.
37. Chowdhry S, Zhang Y, McMahon M, Sutherland C,
Cuadrado A, and Hayes JD. Nrf2 is controlled by two
distinct beta-TrCP recognition motifs in its Neh6 domain,
one of which can be modulated by GSK-3 activity. On-
cogene 32: 3765–3781, 2013.
38. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Sa-
vich GL, Tan TX, Wu MC, Getz G, Lawrence MS, Parker
JS, Li J, Powers S, Kim H, Fischer S, Guindi M, Ghanekar
A, and Chiang DY. Identification of driver genes in he-
patocellular carcinoma by exome sequencing. Hepatology
58: 1693–1702, 2013.
39. Cong ZX, Wang HD, Zhou Y, Wang JW, Pan H, Zhang
DD, Zhang L, and Zhu L. Temozolomide and irradiation
combined treatment-induced Nrf2 activation increases
NRF2 SIGNALING IN CANCER 19
chemoradiation sensitivity in human glioblastoma cells. J
Neurooncol 116: 41–48, 2014.
40. Cullinan SB and Diehl JA. PERK-dependent activation of
Nrf2 contributes to redox homeostasis and cell survival
following endoplasmic reticulum stress. J Biol Chem 279:
20108–20117, 2004.
41. Cullinan SB, Gordan JD, Jin J, Harper JW, and Diehl JA.
The Keap1-BTB protein is an adaptor that bridges Nrf2 to
a Cul3-based E3 ligase: oxidative stress sensing by a
Cul3-Keap1 ligase. Mol Cell Biol 24: 8477–8486, 2004.
42. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman
RJ, and Diehl JA. Nrf2 is a direct PERK substrate and
effector of PERK-dependent cell survival. Mol Cell Biol
23: 7198–7209, 2003.
43. Daga M, Pizzimenti S, Dianzani C, Cucci MA, Cavalli R,
Grattarola M, Ferrara B, Scariot V, Trotta F, and Barrera
G. Ailanthone inhibits cell growth and migration of
cisplatin resistant bladder cancer cells through down-
regulation of Nrf2, YAP, and c-Myc expression. Phyto-
medicine 56: 156–164, 2019.
44. Danilovic DLS, de Mello ES, Frazzato EST, Wakamatsu
A, de Lima Jorge AA, Hoff AO, and Marui S. Oncogenic
mutations in KEAP1 disturbing inhibitory Nrf2-Keap1
interaction: activation of antioxidative pathway in papil-
lary thyroid carcinoma. Head Neck 40: 1271–1278, 2018.
45. Das J, Sarkar A, and Sil PC. Hexavalent chromium in-
duces apoptosis in human liver (HepG2) cells via redox
imbalance. Toxicol Rep 2: 600–608, 2015.
46. Davies KJA and Forman HJ. Does Bach1 & c-Myc de-
pendent redox dysregulation of Nrf2 & adaptive homeo-
stasis decrease cancer risk in ageing? Free Radic Biol Med
134: 708–714, 2019.
47. This reference has been deleted.
48. Davila A, Liu L, Chellappa K, Redpath P, Nakamaru-
Ogiso E, Paolella LM, Zhang Z, Migaud ME, Rabinowitz
JD, and Baur JA. Nicotinamide adenine dinucleotide is
transported into mammalian mitochondria. Elife 7: 33246,
2018.
49. Davila-Gonzalez D, Choi DS, Rosato RR, Granados-
Principal SM, Kuhn JG, Li WF, Qian W, Chen W,
Kozielski AJ, Wong H, Dave B, and Chang JC. Pharma-
cological inhibition of NOS activates ASK1/JNK pathway
augmenting docetaxel-mediated apoptosis in triple-
negative breast cancer. Clin Cancer Res 24: 1152–
1162, 2018.
50. De Francesco EM, Sotgia F, and Lisanti MP. Cancer stem
cells (CSCs): metabolic strategies for their identification
and eradication. Biochem J 475: 1611–1634, 2018.
51. DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z,
Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba,
II, Minna JD, DeBerardinis RJ, and Cantley LC. NRF2
regulates serine biosynthesis in non-small cell lung can-
cer. Nat Genet 47: 1475–1481, 2015.
52. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A,
Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES,
Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue
C, Kern SE, Blair IA, and Tuveson DA. Oncogene-
induced Nrf2 transcription promotes ROS detoxification
and tumorigenesis. Nature 475: 106–109, 2011.
53. Diaz-Ruiz A, Di Francesco A, Carboneau BA, Levan SR,
Pearson KJ, Price NL, Ward TM, Bernier M, de Cabo R,
and Mercken EM. Benefits of caloric restriction in lon-
gevity and chemical-induced tumorigenesis are transmit-
ted independent of NQO1. J Gerontol A Biol Sci Med Sci
74: 155–162, 2019.
54. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K,
Wakabayashi N, Katoh Y, Yamamoto M, and Talalay
P. Direct evidence that sulfhydryl groups of Keap1 are the
sensors regulating induction of phase 2 enzymes that
protect against carcinogens and oxidants. Proc Natl Acad
Sci U S A 99: 11908–11913, 2002.
55. Dodson M, Castro-Portuguez R, and Zhang DD. NRF2
plays a critical role in mitigating lipid peroxidation and
ferroptosis. Redox Biol 11: 101107, 2019.
56. Dong J, Li Y, Xiao H, Luo D, Zhang S, Zhu C, Jiang M,
Cui M, Lu L, and Fan S. Cordycepin sensitizes breast
cancer cells toward irradiation through elevating ROS
production involving Nrf2. Toxicol Appl Pharmacol 364:
12–21, 2019.
57. Duong HQ, Yi YW, Kang HJ, Hong YB, Tang W, Wang
A, Seong YS, and Bae I. Inhibition of NRF2 by PIK-75
augments sensitivity of pancreatic cancer cells to gemci-
tabine. Int J Oncol 44: 959–969, 2014.
58. Eades G, Yang M, Yao Y, Zhang Y, and Zhou Q. miR-
200a regulates Nrf2 activation by targeting Keap1 mRNA
in breast cancer cells. J Biol Chem 286: 40725–40733,
2011.
59. Eggler AL, Liu G, Pezzuto JM, van Breemen RB, and
Mesecar AD. Modifying specific cysteines of the
electrophile-sensing human Keap1 protein is insufficient
to disrupt binding to the Nrf2 domain Neh2. Proc Natl
Acad Sci U S A 102: 10070–10075, 2005.
60. Eskiocak U, Kim SB, Roig AI, Kitten E, Batten K, Cor-
nelius C, Zou YS, Wright WE, and Shay JW. CDDO-Me
protects against space radiation-induced transformation
of human colon epithelial cells. Radiat Res 174: 27–36,
2010.
61. Fabrizio FP, Costantini M, Copetti M, la Torre A, Spar-
aneo A, Fontana A, Poeta L, Gallucci M, Sentinelli S,
Graziano P, Parente P, Pompeo V, De Salvo L, Simone G,
Papalia R, Picardo F, Balsamo T, Flammia GP, Trombetta
D, Pantalone A, Kok K, Paranita F, Muscarella LA, and
Fazio VM. Keap1/Nrf2 pathway in kidney cancer: fre-
quent methylation of KEAP1 gene promoter in clear renal
cell carcinoma. Oncotarget 8: 11187–11198, 2017.
62. Fan Z, Wirth AK, Chen D, Wruck CJ, Rauh M, Buch-
felder M, and Savaskan N. Nrf2-Keap1 pathway promotes
cell proliferation and diminishes ferroptosis. Oncogenesis
6: e371, 2017.
63. Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito
Y, and Shimada M. Nrf2 activation drive macrophages
polarization and cancer cell epithelial-mesenchymal
transition during interaction. Cell Commun Signal 16:
54, 2018.
64. Fetoni AR, Paciello F, Mezzogori D, Rolesi R, Eramo SL,
Paludetti G, and Troiani D. Molecular targets for anti-
cancer redox chemotherapy and cisplatin-induced oto-
toxicity: the role of curcumin on pSTAT3 and Nrf-2
signalling. Br J Cancer 113: 1434–1444, 2015.
65. Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH,
Gajer P, Ravel J, and Goedert JJ. Fecal microbial deter-
minants of fecal and systemic estrogens and estrogen
metabolites: a cross-sectional study. J Transl Med 10: 253,
2012.
66. Fodor T, Szanto M, Abdul-Rahman O, Nagy L, Der A,
Kiss B, and Bai P. Combined treatment of MCF-7 cells
20 SMOLKOVA´ ET AL.
with AICAR and methotrexate, arrests cell cycle and re-
verses Warburg metabolism through AMP-activated pro-
tein kinase (AMPK) and FOXO1. PLoS One 11: e0150232,
2016.
67. Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X,
Ravel J, and Goedert JJ. Associations of the fecal mi-
crobiome with urinary estrogens and estrogen metabolites
in postmenopausal women. J Clin Endocrinol Metab 99:
4632–4640, 2014.
68. Fulop GA, Kiss T, Tarantini S, Balasubramanian P, Ya-
bluchanskiy A, Farkas E, Bari F, Ungvari Z, and Csiszar
A. Nrf2 deficiency in aged mice exacerbates cellular se-
nescence promoting cerebrovascular inflammation. Ger-
oscience 40: 513–521, 2018.
69. Furfaro AL, Piras S, Domenicotti C, Fenoglio D, De Luigi
A, Salmona M, Moretta L, Marinari UM, Pronzato MA,
Traverso N, and Nitti M. Role of Nrf2, HO-1 and GSH in
neuroblastoma cell resistance to bortezomib. PLoS One
11: e0152465, 2016.
70. Furfaro AL, Piras S, Passalacqua M, Domenicotti C,
Parodi A, Fenoglio D, Pronzato MA, Marinari UM,
Moretta L, Traverso N, and Nitti M. HO-1 up-regulation:
a key point in high-risk neuroblastoma resistance to bor-
tezomib. Biochim Biophys Acta 1842: 613–622, 2014.
71. Fuse Y and Kobayashi M. Conservation of the Keap1-
Nrf2 system: an evolutionary journey through stressful
space and time. Molecules 22: pii: E436, 2017.
72. Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A,
Pisegna MA, Tong P, Chen P-H, Boroughs LK, Rodriguez
MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis
F, DeBerardinis RJ, Minna JD, and Heymach JV. LKB1
and KEAP1/NRF2 pathways cooperatively promote met-
abolic reprogramming with enhanced glutamine depen-
dence in KRAS-mutant lung adenocarcinoma. Cancer Res
79: 3251–3267, 2019.
73. Garrido P, Shalaby A, Walsh EM, Keane N, Webber M,
Keane MM, Sullivan FJ, Kerin MJ, Callagy G, Ryan AE,
and Glynn SA. Impact of inducible nitric oxide synthase
(iNOS) expression on triple negative breast cancer out-
come and activation of EGFR and ERK signaling path-
ways. Oncotarget 8: 80568–80588, 2017.
74. Gill JG, Piskounova E, and Morrison SJ. Cancer, oxida-
tive stress, and metastasis. Cold Spring Harb Symp Quant
Biol 81: 163–175, 2016.
75. Girotti AW. Upregulation of nitric oxide in tumor cells as
a negative adaptation to photodynamic therapy. Lasers
Surg Med 50: 590–598, 2018.
76. Goedert JJ, Hua X, Bielecka A, Okayasu I, Milne GL,
Jones GS, Fujiwara M, Sinha R, Wan Y, Xu X, Ravel J,
Shi J, Palm NW, and Feigelson HS. Postmenopausal
breast cancer and oestrogen associations with the IgA-
coated and IgA-noncoated faecal microbiota. Br J Cancer
23: 435, 2018.
77. Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, Falk
RT, Gail MH, Shi J, Ravel J, and Feigelson HS. In-
vestigation of the association between the fecal microbiota
and breast cancer in postmenopausal women: a population-
based case-control pilot study. J Natl Cancer Inst 107: pii:
djv147, 2015.
78. Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder
J, Daemen A, Bakalarski CE, Holcomb T, Shames DS,
Hartmaier RJ, Chmielecki J, Seshagiri S, Gentleman R,
and Stokoe D. Recurrent loss of NFE2L2 Exon 2 is a
mechanism for Nrf2 pathway activation in human cancers.
Cell Rep 16: 2605–2617, 2016.
79. Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP,
Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod
N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML,
and Mak TW. Estrogen controls the survival of BRCA1-
deficient cells via a PI3K-NRF2-regulated pathway. Proc
Natl Acad Sci U S A 111: 4472–4477, 2014.
80. Gorrini C, Harris IS, and Mak TW. Modulation of oxi-
dative stress as an anticancer strategy. Nat Rev Drug
Discov 12: 931–947, 2013.
81. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier
L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M,
Degos F, Clement B, Balabaud C, Chevet E, Laurent A,
Couchy G, Letouze E, Calvo F, and Zucman-Rossi
J. Integrated analysis of somatic mutations and focal copy-
number changes identifies key genes and pathways in
hepatocellular carcinoma. Nat Genet 44: 694–698, 2012.
82. Habib E, Linher-Melville K, Lin H-X, and Singh
G. Expression of xCT and activity of system xc- are
regulated by NRF2 in human breast cancer cells in re-
sponse to oxidative stress. Redox Biol 5: 33, 2015.
83. Hamada S, Shimosegawa T, Taguchi K, Nabeshima T,
Yamamoto M, and Masamune A. Simultaneous K-ras
activation and Keap1 deletion cause atrophy of pancreatic
parenchyma. Am J Physiol Gastrointest Liver Physiol 314:
G65–G74, 2018.
84. Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J,
Ishiguro A, Kijima H, Mimura J, Itoh K, Fukuda S, and
Saijo Y. Methylation of the KEAP1 gene promoter region
in human colorectal cancer. BMC Cancer 12: 66, 2012.
85. Hanahan D and Weinberg RA. Hallmarks of cancer: the
next generation. Cell 144: 646–674, 2011.
86. Hart PC, Ratti BA, Mao M, Ansenberger-Fricano K,
Shajahan-Haq AN, Tyner AL, Minshall RD, and Bonini
MG. Caveolin-1 regulates cancer cell metabolism via
scavenging Nrf2 and suppressing MnSOD-driven glycol-
ysis. Oncotarget 7: 308–322, 2016.
87. Hartikainen JM, Tengstrom M, Winqvist R, Jukkola-
Vuorinen A, Pylkas K, Kosma VM, Soini Y, and Man-
nermaa A. KEAP1 genetic polymorphisms associate with
breast cancer risk and survival outcomes. Clin Cancer Res
21: 1591–1601, 2015.
88. Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling
G, Wakabayashi N, Fujii J, Myers A, and Biswal S. Nrf2-
regulated glutathione recycling independent of biosyn-
thesis is critical for cell survival during oxidative stress.
Free Radic Biol Med 46: 443–453, 2009.
89. Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser
PF, Yan F, Hayes DN, and Major MB. Proteomic analysis
of ubiquitin ligase KEAP1 reveals associated proteins that
inhibit NRF2 ubiquitination. Cancer Res 73: 2199–2210,
2013.
90. Hawkes HJ, Karlenius TC, and Tonissen KF. Regulation
of the human thioredoxin gene promoter and its key
substrates: a study of functional and putative regulatory
elements. Biochim Biophys Acta 1840: 303–314, 2014.
91. Hayden A, Douglas J, Sommerlad M, Andrews L, Gould
K, Hussain S, Thomas GJ, Packham G, and Crabb SJ. The
Nrf2 transcription factor contributes to resistance to cis-
platin in bladder cancer. Urol Oncol 32: 806–814, 2014.
92. Hayes JD and Dinkova-Kostova AT. The Nrf2 regulatory
network provides an interface between redox and inter-
NRF2 SIGNALING IN CANCER 21
mediary metabolism. Trends Biochem Sci 39: 199–218,
2014.
93. He X and Ma Q. NRF2 cysteine residues are critical for
oxidant/electrophile-sensing, Kelch-like ECH-associated
protein-1-dependent ubiquitination-proteasomal degrada-
tion, and transcription activation. Mol Pharmacol 76:
1265–1278, 2009.
94. He X and Ma Q. Critical cysteine residues of Kelch-like
ECH-associated protein 1 in arsenic sensing and sup-
pression of nuclear factor erythroid 2-related factor 2. J
Pharmacol Exp Ther 332: 66–75, 2010.
95. Hegedus C, Kovacs K, Polgar Z, Regdon Z, Szabo E, Ro-
baszkiewicz A, Forman HJ, Martner A, and Virag L. Redox
control of cancer cell destruction. Redox Biol 16: 59–74, 2018.
96. Heinze I, Bens M, Calzia E, Holtze S, Dakhovnik O,
Sahm A, Kirkpatrick JM, Szafranski K, Romanov N,
Sama SN, Holzer K, Singer S, Ermolaeva M, Platzer M,
Hildebrandt T, and Ori A. Species comparison of liver
proteomes reveals links to naked mole-rat longevity and
human aging. BMC Biol 16: 82, 2018.
97. Helleman J, Smid M, Jansen MP, van der Burg ME, and
Berns EM. Pathway analysis of gene lists associated with
platinum-based chemotherapy resistance in ovarian can-
cer: the big picture. Gynecol Oncol 117: 170–176, 2010.
98. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan
V, and Wargo JA. The microbiome, cancer, and cancer
therapy. Nat Med 25: 377–388, 2019.
99. Higgins LG, Kelleher MO, Eggleston IM, Itoh K, Ya-
mamoto M, and Hayes JD. Transcription factor Nrf2
mediates an adaptive response to sulforaphane that pro-
tects fibroblasts in vitro against the cytotoxic effects of
electrophiles, peroxides and redox-cycling agents. Toxicol
Appl Pharmacol 237: 267–280, 2009.
100. Hiramoto K, Satoh H, Suzuki T, Moriguchi T, Pi J, Shi-
mosegawa T, and Yamamoto M. Myeloid lineage-specific
deletion of antioxidant system enhances tumor metastasis.
Cancer Prev Res (Phila) 7: 835–844, 2014.
101. Hirotsu Y, Katsuoka F, Funayama R, Nagashima T,
Nishida Y, Nakayama K, Engel JD, and Yamamoto
M. Nrf2-MafG heterodimers contribute globally to anti-
oxidant and metabolic networks. Nucleic Acids Res 40:
10228–10239, 2012.
102. Hojo T, Maishi N, Towfik AM, Akiyama K, Ohga N, Shin-
doh M, Hida Y, Minowa K, Fujisawa T, and Hida K. ROS
enhance angiogenic properties via regulation of NRF2 in
tumor endothelial cells. Oncotarget 8: 45484–45495, 2017.
103. Hu XF, Yao J, Gao SG, Wang XS, Peng XQ, Yang YT,
and Feng XS. Nrf2 overexpression predicts prognosis and
5-FU resistance in gastric cancer. Asian Pac J Cancer
Prev 14: 5231–5235, 2013.
104. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS,
and Welch DR. Breast cancer metastasis suppressor 1 up-
regulates miR-146, which suppresses breast cancer me-
tastasis. Cancer Res 69: 1279–1283, 2009.
105. Hussong M, Borno ST, Kerick M, Wunderlich A, Franz A,
Sultmann H, Timmermann B, Lehrach H, Hirsch-
Kauffmann M, and Schweiger MR. The bromodomain
protein BRD4 regulates the KEAP1/NRF2-dependent
oxidative stress response. Cell Death Dis 5: e1195, 2014.
106. Ichimura Y, Waguri S, Sou Y-S, Kageyama S, Hasegawa
J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T,
Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H,
Lee M-S, Yoshimori T, Tanaka K, Yamamoto M, and
Komatsu M. Phosphorylation of p62 activates the Keap1-
Nrf2 pathway during selective autophagy. Mol Cell 51:
618–631, 2013.
107. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K,
Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M,
Lee MS, Tanaka K, and Komatsu M. Persistent activation
of Nrf2 through p62 in hepatocellular carcinoma cells. J
Cell Biol 193: 275–284, 2011.
108. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K,
Engel JD, and Yamamoto M. Keap1 represses nuclear
activation of antioxidant responsive elements by Nrf2
through binding to the amino-terminal Neh2 domain.
Genes Dev 13: 76–86, 1999.
109. Ivan J, Major E, Sipos A, Kovacs K, Horvath D, Tamas I,
Bay P,DombradiV, andLontayB.The short-chain fatty acid
propionate inhibits adipogenic differentiation of human
chorion-derived mesenchymal stem cells through the free
fatty acid receptor 2. Stem Cells Dev 26: 1724–1733, 2017.
110. Jain AK and Jaiswal AK. Phosphorylation of tyrosine 568
controls nuclear export of Nrf2. J Biol Chem 292: 2051,
2017.
111. Jana S, Patra K, Jana J, Mandal DP, and Bhattacharjee
S. Nrf-2 transcriptionally activates P21(Cip/WAF1) and
promotes A549 cell survival against oxidative stress in-
duced by H2O2. Chem Biol Interact 285: 59–68, 2018.
112. Jayakumar S, Pal D, and Sandur SK. Nrf2 facilitates repair
of radiation induced DNA damage through homologous
recombination repair pathway in a ROS independent
manner in cancer cells. Mutat Res 779: 33–45, 2015.
113. Jeong Y, Hoang NT, Lovejoy A, Stehr H, Newman AM,
Gentles AJ, Kong W, Truong D, Martin S, Chaudhuri A,
Heiser D, Zhou L, Say C, Carter JN, Hiniker SM, Loo
BW, Jr., West RB, Beachy P, Alizadeh AA, and Diehn
M. Role of KEAP1/NRF2 and TP53 mutations in lung
squamous cell carcinoma development and radiation re-
sistance. Cancer Discov 7: 86–101, 2017.
114. Ji X, Qian J, Rahman SMJ, Siska PJ, Zou Y, Harris BK,
HoeksemaMD, Trenary IA, Heidi C, Eisenberg R, Rathmell
JC, Young JD, and Massion PP. xCT (SLC7A11)-mediated
metabolic reprogramming promotes non-small cell lung
cancer progression. Oncogene 37: 5007–5019, 2018.
115. Jia Y, Chen J, Zhu H, Jia ZH, and Cui MH. Aberrantly
elevated redox sensing factor Nrf2 promotes cancer stem
cell survival via enhanced transcriptional regulation of
ABCG2 and Bcl-2/Bmi-1 genes. Oncol Rep 34: 2296–
2304, 2015.
116. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W,
and Zhang DD. High levels of Nrf2 determine chemore-
sistance in type II endometrial cancer. Cancer Res 70:
5486–5496, 2010.
117. Jiang X, Bao Y, Liu H, Kou X, Zhang Z, Sun F, Qian Z,
Lin Z, Li X, Liu X, Jiang L, and Yang Y. VPS34 stimu-
lation of p62 phosphorylation for cancer progression.
Oncogene 36: 6850–6862, 2017.
118. Jones GS, Spencer Feigelson H, Falk RT, Hua X, Ravel J,
Yu G, Flores R, Gail MH, Shi J, Xu X, and Goedert JJ.
Mammographic breast density and its association with
urinary estrogens and the fecal microbiota in postmeno-
pausal women. PLoS One 14: e0216114, 2019.
119. Joo JC, Hwang JH, Jo E, Kim YR, Kim DJ, Lee KB, Park
SJ, and Jang IS. Cordycepin induces apoptosis by
caveolin-1-mediated JNK regulation of Foxo3a in human
lung adenocarcinoma. Oncotarget 8: 12211–12224, 2017.
120. Joo MS, Kim WD, Lee KY, Kim JH, Koo JH, and Kim
SG. AMPK facilitates nuclear accumulation of Nrf2 by
22 SMOLKOVA´ ET AL.
phosphorylating at serine 550. Mol Cell Biol 36: 1931–
1942, 2016.
121. Ju HQ, Gocho T, Aguilar M, Wu M, Zhuang ZN, Fu J,
Yanaga K, Huang P, and Chiao PJ. Mechanisms of
overcoming intrinsic resistance to gemcitabine in pan-
creatic ductal adenocarcinoma through the redox modu-
lation. Mol Cancer Ther 14: 788–798, 2015.
122. Jung BJ, Yoo HS, Shin S, Park YJ, and Jeon SM. Dys-
regulation of NRF2 in cancer: from molecular mecha-
nisms to therapeutic opportunities. Biomol Ther (Seoul)
26: 57–68, 2018.
123. Kabaria S, Choi DC, Chaudhuri AD, Jain MR, Li H, and
Junn E. MicroRNA-7 activates Nrf2 pathway by targeting
Keap1 expression. Free Radic Biol Med 89: 548–556,
2015.
124. Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery
PA, Forman HJ, Grisham MB, Mann GE, Moore K, Ro-
berts LJ, 2nd, and Ischiropoulos H. Measuring reactive
oxygen and nitrogen species with fluorescent probes:
challenges and limitations. Free Radic Biol Med 52: 1–6,
2012.
125. Kang KA, Piao MJ, Kim KC, Kang HK, Chang WY, Park
IC, Keum YS, Surh YJ, and Hyun JW. Epigenetic modi-
fication of Nrf2 in 5-fluorouracil-resistant colon cancer
cells: involvement of TET-dependent DNA demethyla-
tion. Cell Death Dis 5: e1183, 2014.
126. Kang YP, Torrente L, Falzone A, Elkins CM, Liu M,
Asara JM, Dibble CC, and DeNicola GM. Cysteine di-
oxygenase 1 is a metabolic liability for non-small cell lung
cancer. Elife 8: 45572, 2019.
127. Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL,
and Deeni YY. NRF2 Regulates HER1 signaling pathway
to modulate the sensitivity of ovarian cancer cells to la-
patinib and erlotinib. Oxid Med Cell Longev 2017:
1864578, 2017.
128. Kansanen E, Kuosmanen SM, Leinonen H, and Levonen
AL. The Keap1-Nrf2 pathway: mechanisms of activation
and dysregulation in cancer. Redox Biol 1: 45–49, 2013.
129. Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska
M, Teresiak A, Filas V, Ibbs M, Blizniak R, Luczewski L,
and Lamperska K. 2D and 3D cell cultures—a comparison
of different types of cancer cell cultures. Arch Med Sci 14:
910–919, 2018.
130. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A,
and Yamamoto M. Two domains of Nrf2 cooperatively
bind CBP, a CREB binding protein, and synergistically
activate transcription. Genes Cells 6: 857–868, 2001.
131. Kawamoto Y, Nakamura Y, Naito Y, Torii Y, Kumagai T,
Osawa T, Ohigashi H, Satoh K, Imagawa M, and Uchida
K. Cyclopentenone prostaglandins as potential inducers of
phase II detoxification enzymes. J Biol Chem 275: 11291–
11299, 2000.
132. Kawasaki Y, Okumura H, Uchikado Y, Kita Y, Sasaki K,
Owaki T, Ishigami S, and Natsugoe S. Nrf2 is useful for
predicting the effect of chemoradiation therapy on
esophageal squamous cell carcinoma. Ann Surg Oncol 21:
2347–2352, 2014.
133. Kerins MJ, Liu P, Tian W, Mannheim W, Zhang DD, and
Ooi A. Genome-wide CRISPR screen reveals autophagy
disruption as the convergence mechanism that regulates
the NRF2 transcription factor. Mol Cell Biol 39: pii:
e00037-19, 2019.
134. Kerins MJ and Ooi A. A catalogue of somatic NRF2 gain-
of-function mutations in cancer. Sci Rep 8: 12846, 2018.
135. Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang
AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, Nelson
WG, and Kong AN. Epigenetic DNA methylation of an-
tioxidative stress regulator NRF2 in human prostate can-
cer. Cancer Prev Res (Phila) 7: 1186–1197, 2014.
136. Kiesslich T, Mayr C, and Neureiter D. NRF2: the key to
tumor- and patient-dependent chemosensitivity in biliary
tract cancer? EBioMedicine 49: 9–10, 2019.
137. Kim HR, Kim S, Kim EJ, Park JH, Yang SH, Jeong ET,
Park C, Youn MJ, So HS, and Park R. Suppression of
Nrf2-driven heme oxygenase-1 enhances the chemo-
sensitivity of lung cancer A549 cells toward cisplatin.
Lung Cancer 60: 47–56, 2008.
138. Kim MS, Lee WS, and Jin W. TrkB promotes breast
cancer metastasis via suppression of Runx3 and Keap1
expression. Mol Cells 39: 258–265, 2016.
139. Kim SB, Pandita RK, Eskiocak U, Ly P, Kaisani A, Ku-
mar R, Cornelius C, Wright WE, Pandita TK, and Shay
JW. Targeting of Nrf2 induces DNA damage signaling
and protects colonic epithelial cells from ionizing radia-
tion. Proc Natl Acad Sci U S A 109: E2949–E2955, 2012.
140. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM,
Ku SK, Jung Y, and Kwak MK. NRF2 blockade suppresses
colon tumor angiogenesis by inhibiting hypoxia-induced
activation of HIF-1alpha. Cancer Res 71: 2260–2275, 2011.
141. Kim WD, Kim YW, Cho IJ, Lee CH, and Kim SG.
E-cadherin inhibits nuclear accumulation of Nrf2: impli-
cations for chemoresistance of cancer cells. J Cell Sci 125:
1284–1295, 2012.
142. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY,
Eom HS, Yoo NJ, and Lee SH. Oncogenic NRF2 muta-
tions in squamous cell carcinomas of oesophagus and
skin. J Pathol 220: 446–451, 2010.
143. Kipp AP, Deubel S, Arne´r ESJ, and Johansson K. Time-
and cell-resolved dynamics of redox-sensitive Nrf2, HIF
and NF-jB activities in 3D spheroids enriched for cancer
stem cells. Redox Biol 12: 403–409, 2017.
144. Kitamura H and Motohashi H. NRF2 addiction in cancer
cells. Cancer Sci 109: 900–911, 2018.
145. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y,
Chiba T, Igarashi K, and Yamamoto M. Oxidative stress
sensor Keap1 functions as an adaptor for Cul3-based E3
ligase to regulate proteasomal degradation of Nrf2. Mol
Cell Biol 24: 7130–7139, 2004.
146. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Ko-
bayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A,
Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno
T, Kominami E, Motohashi H, Tanaka K, and Yamamoto
M. The selective autophagy substrate p62 activates the
stress responsive transcription factor Nrf2 through inac-
tivation of Keap1. Nat Cell Biol 12: 213–223, 2010.
147. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF,
Libermann TA, Cannistra SA, and Spentzos D. Carboplatin-
induced gene expression changes in vitro are prognostic of
survival in epithelial ovarian cancer. BMCMed Genomics 1:
59, 2008.
148. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur
N, Sanisetty S, Grammatikos AP, Hecht JL, and Cannistra
SA. Keap1 mutations and Nrf2 pathway activation in epi-
thelial ovarian cancer. Cancer Res 71: 5081–5089, 2011.
149. Kova´cs P, Csonka T, Kova´cs T, Sa´ri Z, Ujlaki G, Sipos A,
Kara´nyi Z, Sze}ocs D, Heged}us C, Uray K, Janko´ L, Kiss
M, Kiss B, Laoui D, Vira´g L, Me´hes G, Bai P, and Miko´
E. Lithocholic acid, a metabolite of the microbiome, in-
NRF2 SIGNALING IN CANCER 23
creases oxidative stress in breast cancer. Cancers (Basel)
11: pii: E1255, 2019.
150. Kova´cs T, Miko´ E, Vida A, Seb}o E´, Toth J, Csonka T,
Boratko´ A, Ujlaki G, Lente G, Kova´cs P, To´th D, A´rkosy
P, Kiss B, Me´hes G, Goedert JJ, and Bai P. Cadaverine, a
metabolite of the microbiome, reduces breast cancer ag-
gressiveness through trace amino acid receptors. Sci Rep
9: 1300, 2019.
151. Kro¨ger C, Afeyan A, Mraz J, Eaton EN, Reinhardt F,
Khodor YL, Thiru P, Bierie B, Ye X, Burge CB, and
Weinberg RA. Acquisition of a hybrid E/M state is es-
sential for tumorigenicity of basal breast cancer cells.
Proc Natl Acad Sci U S A 116: 7353–7362, 2019.
152. Lacher SE, Levings DC, Freeman S, and Slattery
M. Identification of a functional antioxidant response el-
ement at the HIF1A locus. Redox Biol 19: 401–411, 2018.
153. Lam HC, Baglini CV, Lope AL, Parkhitko AA, Liu H-J,
Alesi N, Malinowska IA, Ebrahimi-Fakhari D, Saffari A,
Yu JJ, Pereira A, Khabibullin D, Ogorek B, Nijmeh J,
Kavanagh T, Handen A, Chan SY, Asara JM, Oldham
WM, Diaz-Meco MT, Moscat J, Sahin M, Priolo C, and
Henske EP. p62/SQSTM1 Cooperates with hyperactive
mTORC1 to regulate glutathione production, maintain
mitochondrial integrity, and promote tumorigenesis.
Cancer Res 77: 3255–3267, 2017.
154. Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A,
Santarpia L, and Gyorffy B. miRpower: a web-tool to
validate survival-associated miRNAs utilizing expression
data from 2178 breast cancer patients. Breast Cancer Res
Treat 160: 439–446, 2016.
155. Lau A, Tian W, Whitman SA, and Zhang DD. The pre-
dicted molecular weight of Nrf2: it is what it is not. An-
tioxid Redox Signal 18: 91–93, 2013.
156. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD.
Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262–270,
2008.
157. LeBoeuf SE, Wu WL, Karakousi TR, Karadal B, Jackson
SR, Davidson SM, Wong KK, Koralov SB, Sayin VI, and
Papagiannakopoulos T. Activation of oxidative stress re-
sponse in cancer generates a druggable dependency on
exogenous non-essential amino acids. Cell Metab 31:
339–350.e4, 2020.
158. Lee JD, Cai Q, Shu XO, and Nechuta SJ. The role of
biomarkers of oxidative stress in breast cancer risk and
prognosis: a systematic review of the epidemiologic lit-
erature. J Womens Health (Larchmt) 26: 467–482, 2017.
159. Lee S, Hallis SP, Jung K-A, Ryu D, and Kwak M-K. Im-
pairment of HIF-1a-mediated metabolic adaption by NRF2-
silencing in breast cancer cells. Redox Biol 24: 101210, 2019.
160. Leone A, Roca MS, Ciardiello C, Terranova-Barberio M,
Vitagliano C, Ciliberto G, Mancini R, Di Gennaro E,
Bruzzese F, and Budillon A. Vorinostat synergizes with
EGFR inhibitors in NSCLC cells by increasing ROS via
up-regulation of the major mitochondrial porin VDAC1
and modulation of the c-Myc-NRF2-KEAP1 pathway.
Free Radic Biol Med 89: 287–299, 2015.
161. Levonen A-L, Landar A, Ramachandran A, Ceaser EK,
Dickinson DA, Zanoni G, Morrow JD, and Darley-Usmar
VM. Cellular mechanisms of redox cell signalling: role of
cysteine modification in controlling antioxidant defences
in response to electrophilic lipid oxidation products.
Biochem J 378: 373–382, 2004.
162. Levy JMM, Towers CG, and Thorburn A. Targeting au-
tophagy in cancer. Nat Rev Cancer 17: 528–542, 2017.
163. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW,
Kalivas PW, Massie A, Smolders I, Methner A, Pergande
M, Smith SB, Ganapathy V, and Maher P. The cystine/
glutamate antiporter system x(c)(-) in health and disease:
from molecular mechanisms to novel therapeutic oppor-
tunities. Antioxid Redox Signal 18: 522–555, 2013.
164. Lewis KN, Wason E, Edrey YH, Kristan DM, Nevo E,
and Buffenstein R. Regulation of Nrf2 signaling and
longevity in naturally long-lived rodents. Proc Natl Acad
Sci U S A 112: 3722–3727, 2015.
165. Li N, Wang M, Barajas B, Sioutas C, Williams MA, and
Nel AE. Nrf2 deficiency in dendritic cells enhances the
adjuvant effect of ambient ultrafine particles on allergic
sensitization. J Innate Immun 5: 543–554, 2013.
166. LiWandKongAN.Molecularmechanisms ofNrf2-mediated
antioxidant response.Mol Carcinog 48: 91–104, 2009.
167. Liao H, Zhou Q, Zhang Z, Wang Q, Sun Y, Yi X, and
Feng Y. NRF2 is overexpressed in ovarian epithelial
carcinoma and is regulated by gonadotrophin and sex-
steroid hormones. Oncol Rep 27: 1918–1924, 2012.
168. Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M,
Karakousi TR, Pass HI, Bhutkar AJ, Tsirigos A, Ue-
berheide B, Sayin VI, Papagiannakopoulos T, and Pagano
M. Nrf2 activation promotes lung cancer metastasis by
inhibiting the degradation of Bach1. Cell 178: 316–
329.e18, 2019.
169. Lim JKM, Delaidelli A, Minaker SW, Zhang H-F, Colovic
M, Yang H, Negri GL, von Karstedt S, Lockwood WW,
Schaffer P, Leprivier G, and Sorensen PH. Cystine/glu-
tamate antiporter xCT (SLC7A11) facilitates oncogenic
RAS transformation by preserving intracellular redox
balance. Proc Natl Acad Sci U S A 116: 9433–9442, 2019.
170. Lin DC, Dinh HQ, Xie JJ, Mayakonda A, Silva TC, Jiang
YY, Ding LW, He JZ, Xu XE, Hao JJ, Wang MR, Li C,
Xu LY, Li EM, Berman BP, and Phillip Koeffler
H. Identification of distinct mutational patterns and new
driver genes in oesophageal squamous cell carcinomas
and adenocarcinomas. Gut 67: 1769–1779, 2018.
171. Lin P, Ren Y, Yan X, Luo Y, Zhang H, Kesarwani M, Bu
J, Zhan D, Zhou Y, Tang Y, Zhu S, Xu W, Zhou X, Mei
C, Ma L, Ye L, Hu C, Azam M, Ding W, Jin J, Huang G,
and Tong H. The high NRF2 expression confers chemo-
therapy resistance partly through up-regulated DUSP1 in
myelodysplastic syndromes. Haematologica 104: 485–
496, 2019.
172. Lister A, Nedjadi T, Kitteringham NR, Campbell F,
Costello E, Lloyd B, Copple IM, Williams S, Owen A,
Neoptolemos JP, Goldring CE, and Park BK. Nrf2 is
overexpressed in pancreatic cancer: implications for cell
proliferation and therapy. Mol Cancer 10: 37, 2011.
173. Liu C, Zhao Y, Wang J, Yang Y, Zhang Y, Qu X, Peng S,
Yao Z, Zhao S, He B, Mi Q, Zhu Y, Liu X, Zou J, Zhang
X, and Du Q. FoxO3 reverses 5-fluorouracil resistance in
human colorectal cancer cells by inhibiting the Nrf2/TR1
signaling pathway. Cancer Lett 470: 29–42, 2020.
174. Liu T, Jiang L, Tavana O, and Gu W. The deubiquitylase
OTUB1 mediates ferroptosis via stabilization of
SLC7A11. Cancer Res 79: 1913–1924, 2019.
175. LiuX,Abe-KanohN,LiuY,ZhuB,Munemasa S, Nakamura
T, Murata Y, and Nakamura Y. Inhibition of phosphatidyli-
nositide 3-kinase impairs the benzyl isothiocyanate-induced
accumulation of autophagic molecules and Nrf2 in human
colon cancer cells. Biosci Biotechnol Biochem 81: 2212–
2215, 2017.
24 SMOLKOVA´ ET AL.
176. Lodi M, Priksz D, Fulop GA, Bodi B, Gyongyosi A, Nagy
L, Kovacs A, Kertesz AB, Kocsis J, Edes I, Csanadi Z,
Czuriga I, Kisvarday Z, Juhasz B, Lekli I, Bai P, Toth A,
Papp Z, and Czuriga D. Advantages of prophylactic versus
conventionally scheduled heart failure therapy in an ex-
perimental model of doxorubicin-induced cardiomyopa-
thy. J Transl Med 17: 229, 2019.
177. Lu BC, Li J, Yu WF, Zhang GZ, Wang HM, and Ma HM.
Elevated expression of Nrf2 mediates multidrug resistance
in CD133(+) head and neck squamous cell carcinoma
stem cells. Oncol Lett 12: 4333–4338, 2016.
178. Lu K, Alcivar AL, Ma J, Foo TK, Zywea S, Mahdi A, Huo
Y, Kensler TW, Gatza ML, and Xia B. NRF2 induction
supporting breast cancer cell survival is enabled by oxi-
dative stress-induced DPP3-KEAP1 interaction. Cancer
Res 77: 2881–2892, 2017.
179. Luo L, Chen Y, Wu D, Shou J, Wang S, Ye J, Tang X, and
Wang XJ. Butylated hydroxyanisole induces distinct ex-
pression patterns of Nrf2 and detoxification enzymes in
the liver and small intestine of C57BL/6 mice. Toxicol
Appl Pharmacol 288: 339–348, 2015.
180. Luo M, Shang L, Brooks MD, Jiagge E, Zhu Y, Buschhaus
JM, Conley S, Fath MA, Davis A, Gheordunescu E, Wang
Y, Harouaka R, Lozier A, Triner D, McDermott S, Mer-
ajver SD, Luker GD, Spitz DR, and Wicha MS. Targeting
breast cancer stem cell state equilibrium through modula-
tion of redox signaling. Cell Metab 28: 69–86, 2018.
181. Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta
M, Cheung KL, Ganesan S, Kong AN, Zhang DD, and
Xia B. PALB2 interacts with KEAP1 to promote NRF2
nuclear accumulation and function. Mol Cell Biol 32:
1506–1517, 2012.
182. Ma X, Zhang J, Liu S, Huang Y, Chen B, and Wang
D. Nrf2 knockdown by shRNA inhibits tumor growth and
increases efficacy of chemotherapy in cervical cancer.
Cancer Chemother Pharmacol 69: 485–494, 2012.
183. Mabley JG, Pacher P, Bai P, Wallace R, Goonesekera S,
Virag L, Southan GJ, and Szabo C. Suppression of in-
testinal polyposis in Apcmin/+ mice by targeting the nitric
oxide or poly(ADP-ribose) pathways. Mutat Res 548:
107–116, 2004.
184. Magesh S, Chen Y, and Hu L. Small molecule modulators
of Keap1-Nrf2-ARE pathway as potential preventive and
therapeutic agents. Med Res Rev 32: 687–726, 2012.
185. Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G,
Tanaka Y, Scheffer GL, Chan JY, Manautou JE, Chen Y,
Dalton TP, Yamamoto M, and Klaassen CD. Oxidative
and electrophilic stress induces multidrug resistance-
associated protein transporters via the nuclear factor-E2-
related factor-2 transcriptional pathway. Hepatology 46:
1597–1610, 2007.
186. Malhotra D, Portales-Casamar E, Singh A, Srivastava S,
Arenillas D, Happel C, Shyr C, Wakabayashi N, Kensler
TW, Wasserman WW, and Biswal S. Global mapping of
binding sites for Nrf2 identifies novel targets in cell sur-
vival response through ChIP-Seq profiling and network
analysis. Nucleic Acids Res 38: 5718–5734, 2010.
187. Martinez VD, Vucic EA, Pikor LA, Thu KL, Hubaux R, and
Lam WL. Frequent concerted genetic mechanisms disrupt
multiple components of the NRF2 inhibitor KEAP1/CUL3/
RBX1 E3-ubiquitin ligase complex in thyroid cancer. Mol
Cancer 12: 124, 2013.
188. Martinez VD, Vucic EA, Thu KL, Pikor LA, Hubaux R,
and Lam WL. Unique pattern of component gene dis-
ruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-
ubiquitin ligase complex in serous ovarian cancer. Biomed
Res Int 2014: 159459, 2014.
189. Mato JM and Lu SC. Role of S-adenosyl-L-methionine in
liver health and injury. Hepatology 45: 1306–1312, 2007.
190. McMahon M, Lamont DJ, Beattie KA, and Hayes JD.
Keap1 perceives stress via three sensors for the endoge-
nous signaling molecules nitric oxide, zinc, and alkenals.
Proc Natl Acad Sci U S A 107: 18838–18843, 2010.
191. McMahon M, Thomas N, Itoh K, Yamamoto M, and
Hayes JD. Redox-regulated turnover of Nrf2 is deter-
mined by at least two separate protein domains, the redox-
sensitive Neh2 degron and the redox-insensitive Neh6
degron. J Biol Chem 279: 31556–31567, 2004.
192. McMahon M, Thomas N, Itoh K, Yamamoto M, and
Hayes JD. Dimerization of substrate adaptors can fa-
cilitate cullin-mediated ubiquitylation of proteins by a
‘‘tethering’’ mechanism: a two-site interaction model for
the Nrf2-Keap1 complex. J Biol Chem 281: 24756–24768,
2006.
193. Menegon S, Columbano A, and Giordano S. The dual
roles of NRF2 in cancer. Trends Mol Med 22: 578–593,
2016.
194. Miko E, Kovacs T, Sebo E, Toth J, Csonka T, Ujlaki G,
Sipos A, Szabo J, Mehes G, and Bai P. Microbiome-
microbial metabolome-cancer cell interactions in breast
cancer-familiar, but unexplored. Cells 8: E293, 2019.
195. Miko E, Vida A, and Bai P. Translational aspects of the
microbiome-to be exploited. Cell Biol Toxicol 32: 153–
156, 2016.
196. Miko E, Vida A, Kovacs T, Ujlaki G, Trencsenyi G,
Marton J, Sari Z, Kovacs P, Boratko A, Hujber Z, Csonka
T, Antal-Szalmas P, Watanabe M, Gombos I, Csoka B,
Kiss B, Vigh L, Szabo J, Mehes G, Sebestyen A, Goedert
JJ, and Bai P. Lithocholic acid, a bacterial metabolite
reduces breast cancer cell proliferation and aggressive-
ness. Biochim Biophys Acta 1859: 958–974, 2018.
197. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa
T, Aburatani H, Yamamoto M, and Motohashi H. Nrf2
redirects glucose and glutamine into anabolic pathways in
metabolic reprogramming. Cancer Cell 22: 66–79, 2012.
198. Miura S, Shibazaki M, Kasai S, Yasuhira S, Watanabe A,
Inoue T, Kageshita Y, Tsunoda K, Takahashi K, Akasaka
T, Masuda T, and Maesawa C. A somatic mutation of the
KEAP1 gene in malignant melanoma is involved in ab-
errant NRF2 activation and an increase in intrinsic drug
resistance. J Invest Dermatol 134: 553–556, 2014.
199. Morales AA, Gutman D, Cejas PJ, Lee KP, and Boise LH.
Reactive oxygen species are not required for an arsenic
trioxide-induced antioxidant response or apoptosis. J Biol
Chem 284: 12886–12895, 2009.
200. Mostafavi-Pour Z, Ramezani F, Keshavarzi F, and Samadi
N. The role of quercetin and vitamin C in Nrf2-dependent
oxidative stress production in breast cancer cells. Oncol
Lett 13: 1965–1973, 2017.
201. Muscarella LA, Barbano R, D’Angelo V, Copetti M, Coco
M, Balsamo T, la Torre A, Notarangelo A, Troiano M,
Parisi S, Icolaro N, Catapano D, Valori VM, Pellegrini F,
Merla G, Carella M, Fazio VM, and Parrella P. Regulation
of KEAP1 expression by promoter methylation in malig-
nant gliomas and association with patient’s outcome.
Epigenetics 6: 317–325, 2011.
202. Nguyen T, Sherratt PJ, Huang HC, Yang CS, and Pickett
CB. Increased protein stability as a mechanism that en-
NRF2 SIGNALING IN CANCER 25
hances Nrf2-mediated transcriptional activation of the
antioxidant response element. Degradation of Nrf2 by the
26 S proteasome. J Biol Chem 278: 4536–4541, 2003.
203. Nioi P and Nguyen T. A mutation of Keap1 found in
breast cancer impairs its ability to repress Nrf2 activity.
Biochem Biophys Res Commun 362: 816–821, 2007.
204. Nioi P, Nguyen T, Sherratt PJ, and Pickett CB. The carboxy-
terminal Neh3 domain of Nrf2 is required for transcriptional
activation. Mol Cell Biol 25: 10895–10906, 2005.
205. Niringiyumukiza JD, Cai H, Chen L, Li Y, Wang L, Zhang
M, Xu X, and Xiang W. Protective properties of glycogen
synthase kinase-3 inhibition against doxorubicin-induced
oxidative damage to mouse ovarian reserve. Biomed
Pharmacother 116: 108963, 2019.
206. Numazawa S, Sugihara K, Miyake S, Tomiyama H, Hida
A, Hatsuno M, Yamamoto M, and Yoshida T. Possible
involvement of oxidative stress in 5-fluorouracil-mediated
myelosuppression in mice. Basic Clin Pharmacol Toxicol
108: 40–45, 2011.
207. Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H,
Sato C, and Yamamoto M. Keap1 is a forked-stem dimer
structure with two large spheres enclosing the intervening,
double glycine repeat, and C-terminal domains. Proc Natl
Acad Sci U S A 107: 2842–2847, 2010.
208. Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kah-
noski R, Anema J, Craig D, Carpten J, Teh BT, and Furge
KA. CUL3 and NRF2 mutations confer an NRF2 activa-
tion phenotype in a sporadic form of papillary renal cell
carcinoma. Cancer Res 73: 2044–2051, 2013.
209. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova
V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ,
Zhou M, Gardie B, Molinie V, Richard S, Tan PH, Teh
BT, and Furge KA. An antioxidant response phenotype
shared between hereditary and sporadic type 2 papillary
renal cell carcinoma. Cancer Cell 20: 511–523, 2011.
210. Ozgen M, Koca SS, Karatas A, Dagli AF, Erman F, Gun-
dogdu B, Sahin K, and Isik A. Lapatinib ameliorates ex-
perimental arthritis in rats. Inflammation 38: 252–259, 2015.
211. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM,
Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves
JT, and Szabo C. Potent metalloporphyrin peroxynitrite
decomposition catalyst protects against the development
of doxorubicin-induced cardiac dysfunction. Circulation
107: 896–904, 2003.
212. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G,
and Szabo C. Activation of poly(ADP-ribose) polymerase
contributes to development of doxorubicin-induced heart
failure. J Pharmacol Exp Ther 300: 862–867, 2002.
213. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Schar-
lock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S,
and Yamamoto M. Structural basis for defects of Keap1
activity provoked by its point mutations in lung cancer.
Mol Cell 21: 689–700, 2006.
214. Peiris-Pages M, Martinez-Outschoorn UE, Pestell RG,
Sotgia F, and Lisanti MP. Cancer stem cell metabolism.
Breast Cancer Res 18: 55, 2016.
215. Phuong NT, Kim SK, Im JH, Yang JW, Choi MC, Lim SC,
Lee KY, Kim YM, Yoon JH, and Kang KW. Induction of
methionine adenosyltransferase 2A in tamoxifen-resistant
breast cancer cells. Oncotarget 7: 13902–13916, 2016.
216. Phuong NTT, Kim SK, Lim SC, Kim HS, Kim TH, Lee
KY, Ahn S-G, Yoon J-H, and Kang KW. Role of PTEN
promoter methylation in tamoxifen-resistant breast cancer
cells. Breast Cancer Res Treat 130: 73–83, 2011.
217. Pirpour Tazehkand A, Akbarzadeh M, Velaie K, Sadeghi
MR, and Samadi N. The role of Her2-Nrf2 axis in in-
duction of oxaliplatin resistance in colon cancer cells.
Biomed Pharmacother 103: 755–766, 2018.
218. Pons DG, Nadal-Serrano M, Torrens-Mas M, Valle A,
Oliver J, and Roca P. UCP2 inhibition sensitizes breast
cancer cells to therapeutic agents by increasing oxidative
stress. Free Radic Biol Med 86: 67–77, 2015.
219. Primiano T, Sutter TR, and Kensler TW. Antioxidant-
inducible genes. Adv Pharmacol 38: 293–328, 1997.
220. Qu J, Zhang L, Li L, and Su Y. miR-148b functions as a
tumor suppressor by targeting endoplasmic reticulum
metallo protease 1 in human endometrial cancer cells.
Oncol Res 27: 81–88, 2018.
221. QueL,HeL,YuC,YinW,MaL,CaoB, andYuS.Activation
of Nrf2-ARE signaling mitigates cyclophosphamide-induced
myelosuppression. Toxicol Lett 262: 17–26, 2016.
222. Rabinowitz JD and White E. Autophagy and metabolism.
Science 330: 1344–1348, 2010.
223. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD,
and Cuadrado A. SCF/{beta}-TrCP promotes glycogen
synthase kinase 3-dependent degradation of the Nrf2
transcription factor in a Keap1-independent manner. Mol
Cell Biol 31: 1121–1133, 2011.
224. Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG,
Cotte A, Jaworski T, Tobon-Velasco JC, Devijver H,
Garcia-Mayoral MF, Van Leuven F, Hayes JD, Bertho G,
and Cuadrado A. Structural and functional characteriza-
tion of Nrf2 degradation by the glycogen synthase kinase
3/beta-TrCP axis. Mol Cell Biol 32: 3486–3499, 2012.
225. Ranganathan S, Krishnan A, and Sivasithambaram ND.
Significance of twist and iNOS expression in human
breast carcinoma. Mol Cell Biochem 412: 41–47, 2016.
226. Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J,
Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak
AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R,
Berger MF, Moreira AL, Travis WD, Rudin CM, and
Ladanyi M. Next-generation sequencing of pulmonary
large cell neuroendocrine carcinoma reveals small cell
carcinoma-like and non-small cell carcinoma-like subsets.
Clin Cancer Res 22: 3618–3629, 2016.
227. Reuter S, Gupta SC, Chaturvedi MM, and Aggarwal BB.
Oxidative stress, inflammation, and cancer: how are they
linked? Free Radic Biol Med 49: 1603–1616, 2010.
228. Riz I, Hawley TS, Marsal JW, Hawley RG, Riz I, Hawley
TS, Marsal JW, and Hawley RG. Noncanonical SQSTM1/
p62-Nrf2 pathway activation mediates proteasome inhib-
itor resistance in multiple myeloma cells via redox, met-
abolic and translational reprogramming. Oncotarget 7:
66360–66385, 2016.
229. Rocha CR, Kajitani GS, Quinet A, Fortunato RS, and
Menck CF. NRF2 and glutathione are key resistance me-
diators to temozolomide in glioma and melanoma cells.
Oncotarget 7: 48081–48092, 2016.
230. Roh JL, Kim EH, Jang H, and Shin D. Nrf2 inhibition
reverses the resistance of cisplatin-resistant head and neck
cancer cells to artesunate-induced ferroptosis. Redox Biol
11: 254–262, 2017.
231. Roininen N, Haapasaari KM, and Karihtala P. The role of
redox-regulating enzymes in inoperable breast cancers
treated with neoadjuvant chemotherapy. Oxid Med Cell
Longev 2017: 2908039, 2017.
232. Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla
K, Rogowska-Wrzesinska A, Hardisson D, Serrano M, and
26 SMOLKOVA´ ET AL.
Cuadrado A. The PTEN/NRF2 axis promotes human car-
cinogenesis. Antioxid Redox Signal 21: 2498–2514, 2014.
233. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, and
Spendlove I. The ubiquitin-binding protein p62 is ex-
pressed in breast cancers showing features of aggressive
disease. Endocr Relat Cancer 14: 73–80, 2007.
234. Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX,
LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A,
Sanchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT,
Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies
A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL,
Rudin CM, Pass HI, Vander Heiden MG, Jacks T, and
Papagiannakopoulos T. Keap1 loss promotes Kras-driven
lung cancer and results in dependence on glutaminolysis.
Nat Med 23: 1362–1368, 2017.
235. Ron D and Walter P. Signal integration in the endoplasmic
reticulum unfolded protein response. Nat Rev Mol Cell
Biol 8: 519–529, 2007.
236. RotaC,Chignell CF, andMasonRP. Evidence for free radical
formation during the oxidation of 2¢-7¢-dichlorofluorescin to
the fluorescent dye 2¢-7¢-dichlorofluorescein by horseradish
peroxidase: possible implications for oxidative stress mea-
surements. Free Radic Biol Med 27: 873–881, 1999.
237. Rushworth SA and Macewan DJ. The role of nrf2 and cy-
toprotection in regulating chemotherapy resistance of human
leukemia cells. Cancers (Basel) 3: 1605–1621, 2011.
238. Rushworth SA, Zaitseva L, Murray MY, Shah NM,
Bowles KM, and MacEwan DJ. The high Nrf2 expression
in human acute myeloid leukemia is driven by NF-kappaB
and underlies its chemo-resistance. Blood 120: 5188–
5198, 2012.
239. Ryoo IG, Choi BH, Ku SK, and Kwak MK. High CD44
expression mediates p62-associated NFE2L2/NRF2 acti-
vation in breast cancer stem cell-like cells: implications for
cancer stem cell resistance. Redox Biol 17: 246–258, 2018.
240. Ryoo IG, Choi BH, and Kwak MK. Activation of NRF2
by p62 and proteasome reduction in sphere-forming breast
carcinoma cells. Oncotarget 6: 8167–8184, 2015.
241. Sadeghi MR, Jeddi F, Soozangar N, Somi MH, and Sa-
madi N. The role of Nrf2-Keap1 axis in colorectal cancer,
progression, and chemoresistance. Tumour Biol 39:
1010428317705510, 2017.
242. Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T,
Takagi K, Hirose Y, Nagahashi M, Iso T, Fukutomi T,
OhishiM, EndoK,Uemura T, Nishito Y,Okuda S, ObataM,
Kouno T, Imamura R, Tada Y, Obata R, Yasuda D, Taka-
hashi K, Fujimura T, Pi J, LeeM-S, UenoT,Ohe T,Mashino
T, Wakai T, Kojima H, Okabe T, Nagano T, Motohashi H,
Waguri S, Soga T, Yamamoto M, Tanaka K, and Komatsu
M. p62/Sqstm1 promotes malignancy of HCV-positive he-
patocellular carcinoma through Nrf2-dependent metabolic
reprogramming. Nat Commun 7: 12030, 2016.
243. Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P,
Rubinstein M, Kopecka J, and Riganti C. PERK induces
resistance to cell death elicited by endoplasmic reticulum
stress and chemotherapy. Mol Cancer 16: 91, 2017.
244. Samatiwat P, Prawan A, Senggunprai L, and Kukongvir-
iyapan V. Repression of Nrf2 enhances antitumor effect of
5-fluorouracil and gemcitabine on cholangiocarcinoma
cells. Naunyn Schmiedebergs Arch Pharmacol 388: 601–
612, 2015.
245. Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li
Z, Miele MM, Lailler N, Zhao C, de Stanchina E, Viale A,
Akkari L, Lowe SW, Ciriello G, Hendrickson RC, and
Wendel HG. The oncogenic action of NRF2 depends on
de-glycation by fructosamine-3-kinase. Cell 178: 807–
819, 2019.
246. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM,
Suzuki T, Winnard PT, Jr., Raman V, Ebina M, Nukiwa T,
and Yamamoto M. Nrf2-deficiency creates a responsive
microenvironment for metastasis to the lung. Carcino-
genesis 31: 1833–1843, 2010.
247. Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur
D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR,
Zavitsanou AM, Ubriaco J, Muir A, Karagiannis D,
Morris PJ, Thomas CJ, Possemato R, Vander Heiden MG,
and Papagiannakopoulos T. Activation of the NRF2 an-
tioxidant program generates an imbalance in central car-
bon metabolism in cancer. eLife 6: pii: e28083, 2017.
248. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines
Z, Irie HY, Gao S, Puigserver P, and Brugge JS. Anti-
oxidant and oncogene rescue of metabolic defects caused
by loss of matrix attachment. Nature 461: 109–113, 2009.
249. Schatten H. Cell and Molecular Biology of Breast Cancer
New York, NY: Humana Press, 2013.
250. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen
LC, Smith KD, Cushing RC, and Seagroves TN. Hypoxia-
inducible factor 1a promotes primary tumor growth and
tumor-initiating cell activity in breast cancer. Breast
Cancer Res 14: R6, 2012.
251. Sekhar KR, Rachakonda G, and Freeman ML. Cysteine-
based regulation of the CUL3 adaptor protein Keap1.
Toxicol Appl Pharmacol 244: 21–26, 2010.
252. Semenza GL. Regulation of mammalian O 2 homeostasis
by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:
551–578, 1999.
253. Shah NM, Rushworth SA, Murray MY, Bowles KM, and
MacEwan DJ. Understanding the role of NRF2-regulated
miRNAs in human malignancies. Oncotarget 4: 1130–
1142, 2013.
254. Shao J, Glorieux C, Liao J, Chen P, Lu W, Liang Z, Wen
S, Hu Y, and Huang P. Impact of Nrf2 on tumour growth
and drug sensitivity in oncogenic K-ras-transformed cells
in vitro and in vivo. Free Radic Res 52: 661–671, 2018.
255. Shi L, Wu L, Chen Z, Yang J, Chen X, Yu F, Zheng F, and
Lin X. MiR-141 Activates Nrf2-dependent antioxidant
pathway via down-regulating the expression of Keap1 con-
ferring the resistance of hepatocellular carcinoma cells to
5-fluorouracil. Cell Physiol Biochem 35: 2333–2348, 2015.
256. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Ya-
mamoto M, and Hirohashi S. Genetic alteration of Keap1
confers constitutive Nrf2 activation and resistance to
chemotherapy in gallbladder cancer. Gastroenterology
135: 1358–1368, 2008.
257. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H,
Aoyagi K, Yoshimatsu Y, Tachimori Y, KushimaR, Kiyono
T, and Yamamoto M. NRF2 mutation confers malignant
potential and resistance to chemoradiation therapy in ad-
vanced esophageal squamous cancer. Neoplasia 13: 864–
873, 2011.
258. Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M,
and Uchida K. 15-Deoxy-D 12,14 -prostaglandin J2. J
Biol Chem 277: 10459–10466, 2002.
259. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R,
Tsuta K, Asamura H, Yamamoto M, and Hirohashi
S. Cancer related mutations in NRF2 impair its recogni-
tion by Keap1-Cul3 E3 ligase and promote malignancy.
Proc Natl Acad Sci U S A 105: 13568–13573, 2008.
NRF2 SIGNALING IN CANCER 27
260. Shim GS, Manandhar S, Shin DH, Kim TH, and Kwak
MK. Acquisition of doxorubicin resistance in ovarian
carcinoma cells accompanies activation of the NRF2
pathway. Free Radic Biol Med 47: 1619–1631, 2009.
261. Shimizu T, Inoue K, Hachiya H, Shibuya N, Aoki T, and
Kubota K. Accumulation of phosphorylated p62 is associ-
ated with NF-E2-related factor 2 activation in hepatocellular
carcinoma. J Hepatobiliary Pancreat Sci 23: 467–471, 2016.
262. Shin CS, Mishra P, Watrous JD, Carelli V, D’Aurelio M,
Jain M, and Chan DC. The glutamate/cystine xCT anti-
porter antagonizes glutamine metabolism and reduces
nutrient flexibility. Nat Commun 8: 15074, 2017.
263. Shirasaki K, Taguchi K, Unno M, Motohashi H, and
Yamamoto M. NF-E2-related factor 2 promotes compen-
satory liver hypertrophy after portal vein branch ligation
in mice. Hepatology 59: 2371–2382, 2014.
264. Sid B, Glorieux C, Valenzuela M, Rommelaere G, Najimi
M, Dejeans N, Renard P, Verrax J, and Calderon PB. AI-
CAR induces Nrf2 activation by an AMPK-independent
mechanism in hepatocarcinoma cells. Biochem Pharmacol
91: 168–180, 2014.
265. Silva MM, Rocha CRR, Kinker GS, Pelegrini AL, and
Menck CFM. The balance between NRF2/GSH antioxidant
mediated pathway and DNA repair modulates cisplatin
resistance in lung cancer cells. Sci Rep 9: 17639, 2019.
266. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S,
Hoque MO, Herman JG, Baylin SB, Sidransky D, Gab-
rielson E, Brock MV, and Biswal S. Dysfunctional
KEAP1-NRF2 interaction in non-small-cell lung cancer.
PLoS Med 3: e420, 2006.
267. Singh B, Bhat NK, and Bhat HK. Induction of NAD(P)H-
quinone oxidoreductase 1 by antioxidants in female ACI
rats is associated with decrease in oxidative DNA damage
and inhibition of estrogen-induced breast cancer. Carci-
nogenesis 33: 156–163, 2012.
268. Singh B, Chatterjee A, Ronghe AM, Bhat NK, and Bhat
HK. Antioxidant-mediated up-regulation of OGG1 via
NRF2 induction is associated with inhibition of oxidative
DNA damage in estrogen-induced breast cancer. BMC
Cancer 13: 253, 2013.
269. Singh B, Ronghe AM, Chatterjee A, Bhat NK, and Bhat
HK. MicroRNA-93 regulates NRF2 expression and is
associated with breast carcinogenesis. Carcinogenesis 34:
1165–1172, 2013.
270. Singh B, Shoulson R, Chatterjee A, Ronghe A, Bhat NK,
Dim DC, and Bhat HK. Resveratrol inhibits estrogen-
induced breast carcinogenesis through induction of
NRF2-mediated protective pathways. Carcinogenesis 35:
1872–1880, 2014.
271. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber
TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S,
Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J,
Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu
C, Parmigiani G, Park BH, Bachman KE, Papadopoulos
N, Vogelstein B, Kinzler KW, and Velculescu VE. The
consensus coding sequences of human breast and colo-
rectal cancers. Science 314: 268–274, 2006.
272. Sompakdee V, Prawan A, Senggunprai L, Kukongvir-
iyapan U, Samathiwat P, Wandee J, and Kukongviriyapan
V. Suppression of Nrf2 confers chemosensitizing effect
through enhanced oxidant-mediated mitochondrial dys-
function. Biomed Pharmacother 101: 627–634, 2018.
273. Sulaiman A, McGarry S, Han X, Liu S, and Wang
L. CSCs in breast cancer-one size does not fit all: ther-
apeutic advances in targeting heterogeneous epithelial
and mesenchymal CSCs. Cancers (Basel) 11: pii: E1128,
2019.
274. Sun X, Liu D, Xue Y, and Hu X. Enforced miR-144-3p
expression as a non-invasive biomarker for the acute
myeloid leukemia patients mainly by targeting NRF2.
Clin Lab 63: 679–687, 2017.
275. Sun X, Wang S, Gai J, Guan J, Li J, Li Y, Zhao J, Zhao C,
Fu L, and Li Q. SIRT5 promotes cisplatin resistance in
ovarian cancer by suppressing DNA damage in a ROS-
dependent manner via regulation of the Nrf2/HO-1 path-
way. Front Oncol 9: 754, 2019.
276. Sun Y, Abdul Aziz A, Bowles K, and Rushworth S. High
NRF2 expression controls endoplasmic reticulum stress
induced apoptosis in multiple myeloma. Cancer Lett 412:
37–45, 2018.
277. Suzuki T, Motohashi H, and Yamamoto M. Toward
clinical application of the Keap1-Nrf2 pathway. Trends
Pharmacol Sci 34: 340–346, 2013.
278. Taguchi K, Hirano I, Itoh T, Tanaka M, Miyajima A,
Suzuki A, Motohashi H, and Yamamoto M. Nrf2 enhances
cholangiocyte expansion in Pten-deficient livers. Mol Cell
Biol 34: 900–913, 2014.
279. Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E,
Wong PK, and Zhang DD. Oncogenic KRAS confers
chemoresistance by upregulating NRF2. Cancer Res 74:
7430–7441, 2014.
280. Tebay LE, Robertson H, Durant ST, Vitale SR, Penning
TM, Dinkova-Kostova AT, and Hayes JD. Mechanisms of
activation of the transcription factor Nrf2 by redox
stressors, nutrient cues, and energy status and the path-
ways through which it attenuates degenerative disease.
Free Radic Biol Med 88: 108–146, 2015.
281. Teng Y, Zhao H, Gao L, Zhang W, Shull AY, and Shay
C. FGF19 protects hepatocellular carcinoma cells against
endoplasmic reticulum stress via activation of FGFR4-
GSK3beta-Nrf2 signaling. Cancer Res 77: 6215–6225,
2017.
282. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW,
Yamamoto M, and Biswal S. Identification of Nrf2-
regulated genes induced by the chemopreventive agent
sulforaphane by oligonucleotide microarray. Cancer Res
62: 5196–5203, 2002.
283. Tian Y, Wu K, Liu Q, Han N, Zhang L, Chu Q, and Chen
Y. Modification of platinum sensitivity by KEAP1/NRF2
signals in non-small cell lung cancer. J Hematol Oncol 9: 83,
2016.
284. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro
M, Daemen A, Hu M, Chan DA, Ethier SP, van ‘t Veer
LJ, Polyak K, McCormick F, and Gray JW. Glutamine
sensitivity analysis identifies the xCT antiporter as a
common triple-negative breast tumor therapeutic target.
Cancer Cell 24: 450–465, 2013.
285. To C, Ringelberg CS, Royce DB, Williams CR, Rising-
song R, Sporn MB, and Liby KT. Dimethyl fumarate and
the oleanane triterpenoids, CDDO-imidazolide and
CDDO-methyl ester, both activate the Nrf2 pathway but
have opposite effects in the A/J model of lung carcino-
genesis. Carcinogenesis 36: 769–781, 2015.
286. Tonelli C, Chio IIC, and Tuveson DA. Transcriptional
regulation by Nrf2. Antioxid Redox Signal 29: 1727–
1745, 2018.
287. Tong KI, Kobayashi A, Katsuoka F, and Yamamoto
M. Two-site substrate recognition model for the Keap1-
28 SMOLKOVA´ ET AL.
Nrf2 system: a hinge and latch mechanism. Biol Chem
387: 1311–1320, 2006.
288. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hir-
otsu Y, Yokoyama S, and Yamamoto M. Different elec-
trostatic potentials define ETGE and DLG motifs as hinge
and latch in oxidative stress response. Mol Cell Biol 27:
7511–7521, 2007.
289. Tsuji Y. JunD activates transcription of the human
ferritin H gene through an antioxidant response ele-
ment during oxidative stress. Oncogene 24: 7567–7578,
2005.
290. Ungvari Z, Tarantini S, Nyul-Toth A, Kiss T, Ya-
bluchanskiy A, Csipo T, Balasubramanian P, Lipecz A,
Benyo Z, and Csiszar A. Nrf2 dysfunction and impaired
cellular resilience to oxidative stressors in the aged vas-
culature: from increased cellular senescence to the path-
ogenesis of age-related vascular diseases. Geroscience 41:
727–738, 2019.
291. van der Wijst MG, Huisman C, Mposhi A, Roelfes G, and
Rots MG. Targeting Nrf2 in healthy and malignant ovar-
ian epithelial cells: protection versus promotion. Mol
Oncol 9: 1259–1273, 2015.
292. Venkatraman G, Benesch MG, Tang X, Dewald J,
McMullen TP, and Brindley DN. Lysophosphatidate
signaling stabilizes Nrf2 and increases the expression of
genes involved in drug resistance and oxidative stress
responses: implications for cancer treatment. FASEB J
29: 772–785, 2015.
293. Venugopal R and Jaiswal AK. Nrf2 and Nrf1 in associa-
tion with Jun proteins regulate antioxidant response
element-mediated expression and coordinated induction of
genes encoding detoxifying enzymes. Oncogene 17:
3145–3156, 1998.
294. Walker A, Singh A, Tully E, Woo J, Le A, Nguyen T,
Biswal S, Sharma D, and Gabrielson E. Nrf2 signaling and
autophagy are complementary in protecting breast cancer
cells during glucose deprivation. Free Radic Biol Med
120: 407–413, 2018.
295. Walsh EM, Keane MM, Wink DA, Callagy G, and Glynn
SA. Review of triple negative breast cancer and the im-
pact of inducible nitric oxide synthase on tumor biology
and patient outcomes. Crit Rev Oncog 21: 333–351, 2016.
296. Wang B, Teng Y, and Liu Q. MicroRNA-153 regulates
NRF2 expression and is associated with breast carcino-
genesis. Clin Lab 62: 39–47, 2016.
297. Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, Li Y, Li
Y, Luo L, Hayes JD, Wang XJ, and Tang X. RXRalpha
inhibits the NRF2-ARE signaling pathway through a di-
rect interaction with the Neh7 domain of NRF2. Cancer
Res 73: 3097–3108, 2013.
298. Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, Ding HF,
Zhang J, Wang H, Chen X, and Yan C. ATF3 promotes
erastin-induced ferroptosis by suppressing system Xc. Cell
Death Differ 27: 662–675, 2020.
299. Wang N, Song L, Xu Y, Zhang L, Wu Y, Guo J, Ji W, Li
L, Zhao J, Zhang X, and Zhan L. Loss of scribble confers
cisplatin resistance during NSCLC chemotherapy via
Nox2/ROS and Nrf2/PD-L1 signaling. EBioMedicine 47:
65–77, 2019.
300. Wang Q, Ma J, Lu Y, Zhang S, Huang J, Chen J, Bei JX,
Yang K, Wu G, Huang K, Chen J, and Xu S. CDK20
interacts with KEAP1 to activate NRF2 and promotes
radiochemoresistance in lung cancer cells. Oncogene 36:
5321–5330, 2017.
301. Wang R, An J, Ji F, Jiao H, Sun H, and Zhou
D. Hypermethylation of the Keap1 gene in human lung
cancer cell lines and lung cancer tissues. Biochem Biophys
Res Commun 373: 151–154, 2008.
302. Wang SW, Xu Y, Weng YY, Fan XY, Bai YF, Zheng
XY, Lou LJ, and Zhang F. Astilbin ameliorates cisplatin-
induced nephrotoxicity through reducing oxidative stress
and inflammation. Food Chem Toxicol 114: 227–236,
2018.
303. Wang T, Liu Q, and Duan L. MBNL1 regulates resistance
of HeLa cells to cisplatin via Nrf2. Biochem Biophys Res
Commun 522: 763–769, 2020.
304. Wang XJ, Hayes JD, Henderson CJ, and Wolf CR.
Identification of retinoic acid as an inhibitor of tran-
scription factor Nrf2 through activation of retinoic acid
receptor alpha. Proc Natl Acad Sci U S A 104: 19589–
19594, 2007.
305. Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu
J, and Tang X. Oxaliplatin activates the Keap1/Nrf2
antioxidant system conferring protection against the cy-
totoxicity of anticancer drugs. Free Radic Biol Med 70:
68–77, 2014.
306. Wang YY, Chen J, Liu XM, Zhao R, and Zhe H. Nrf2-
mediated metabolic reprogramming in cancer. Oxid Med
Cell Longev 2018: 9304091, 2018.
307. Wang Z, Chen Z, Jiang Z, Luo P, Liu L, Huang Y, Wang
H, Wang Y, Long L, Tan X, Liu D, Jin T, Wang Y, Wang
Y, Liao F, Zhang C, Chen L, Gan Y, Liu Y, Yang F,
Huang C, Miao H, Chen J, Cheng T, Fu X, and Shi
C. Cordycepin prevents radiation ulcer by inhibiting cell
senescence via NRF2 and AMPK in rodents. Nat Commun
10: 2538, 2019.
308. Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang
Q, Munson PJ, Raghavachari N, White T, Tweito MM,
Dunleavy K, Ye Y, Wilson WH, and Wiestner
A. Treatment-induced oxidative stress and cellular anti-
oxidant capacity determine response to bortezomib in
mantle cell lymphoma. Clin Cancer Res 17: 5101–5112,
2011.
309. Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M,
Yao H, Ziegler DV, Xu X, Ghosh T, Mondal T, Kanduri
C, Lindahl P, Sayin VI, and Bergo MO. BACH1 stabili-
zation by antioxidants stimulates lung cancer metastasis.
Cell 178: 330–345, 2019.
310. Winkel AF, Engel CK, Margerie D, Kannt A, Szillat H,
Glombik H, Kallus C, Ruf S, Gussregen S, Riedel J,
Herling AW, von Knethen A, Weigert A, Brune B, and
Schmoll D. Characterization of RA839, a noncovalent
small molecule binder to Keap1 and selective activator of
Nrf2 signaling. J Biol Chem 290: 28446–28455, 2015.
311. Wong TF, Yoshinaga K, Monma Y, Ito K, Niikura H,
Nagase S, Yamamoto M, and Yaegashi N. Association of
keap1 and nrf2 genetic mutations and polymorphisms with
endometrioid endometrial adenocarcinoma survival. Int J
Gynecol Cancer 21: 1428–1435, 2011.
312. Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC,
Rosenbach MD, Corr M, Schwab RB, and Carson DA.
Nrf2 responses and the therapeutic selectivity of electro-
philic compounds in chronic lymphocytic leukemia. Proc
Natl Acad Sci U S A 107: 7479–7484, 2010.
313. Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T,
Wong PK, Chapman E, Fang D, and Zhang DD. Hrd1
suppresses Nrf2-mediated cellular protection during liver
cirrhosis. Genes Dev 28: 708–722, 2014.
NRF2 SIGNALING IN CANCER 29
314. Wu YW, Lin CF, Lin YS, Su WC, and Chiu WH. Au-
tophagy regulates vinorelbine sensitivity due to continued
Keap1-mediated ROS generation in lung adenocarcinoma
cells. Cell Death Discov 4: 33, 2018.
315. Xia M, Yu H, Gu S, Xu Y, Su J, Li H, Kang J, and Cui M.
p62/SQSTM1 is involved in cisplatin resistance in human
ovarian cancer cells via the Keap1-Nrf2-ARE system. Int
J Oncol 45: 2341–2348, 2014.
316. Xiang Y, Ye W, Huang C, Yu D, Chen H, Deng T, Zhang
F, Lou B, Zhang J, Shi K, Chen B, and Zhou M. Brusatol
enhances the chemotherapy efficacy of gemcitabine in
pancreatic cancer via the Nrf2 signalling pathway. Oxid
Med Cell Longev 2018: 2360427, 2018.
317. Xu D, Li X, Shao F, Lv G, Lv H, Lee J-H, Qian X, Wang
Z, Xia Y, Du L, Zheng Y, Wang H, Lyu J, and Lu Z. The
protein kinase activity of fructokinase A specifies the
antioxidant responses of tumor cells by phosphorylating
p62. Sci Adv 5: eaav4570, 2019.
318. Xu X, zur Hausen A, Coy JF, and Lo¨chelt M. Transketolase-
like protein 1 (TKTL1) is required for rapid cell growth and
full viability of human tumor cells. Int J Cancer 124: 1330–
1337, 2009.
319. Yamaguchi Y, Kamai T, Higashi S, Murakami S, Arai K,
Shirataki H, and Yoshida KI. Nrf2 gene mutation and
single nucleotide polymorphism rs6721961 of the Nrf2
promoter region in renal cell cancer. BMC Cancer 19:
1137, 2019.
320. Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K,
and Inazawa J. The impact of miRNA-based molecular
diagnostics and treatment of NRF2-stabilized tumors. Mol
Cancer Res 12: 58–68, 2014.
321. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J,
Maher J, Motohashi H, and Yamamoto M. Physiological
significance of reactive cysteine residues of Keap1 in
determining Nrf2 activity. Mol Cell Biol 28: 2758–2770,
2008.
322. Yang H, Huang Z-Z, Zeng Z, Chen C, Selby RR, and Lu
SC. Role of promoter methylation in increased methionine
adenosyltransferase 2A expression in human liver cancer.
Am J Physiol Gastrointest Liver Physiol 280: G184–G190,
2001.
323. Yang KQ, Liu Y, Huang QH, Mo N, Zhang QY, Meng
QG, and Cheng JW. Bone marrow-derived mesenchymal
stem cells induced by inflammatory cytokines produce
angiogenetic factors and promote prostate cancer growth.
BMC Cancer 17: 878, 2017.
324. Yang M, Yao Y, Eades G, Zhang Y, and Zhou Q. MiR-28
regulates Nrf2 expression through a Keap1-independent
mechanism. Breast Cancer Res Treat 129: 983–991, 2011.
325. Yang Y, Luo L, Cai X, Fang Y, Wang J, Chen G, Yang J,
Zhou Q, Sun X, Cheng X, Yan H, Lu W, Hu C, and Cao
P. Nrf2 inhibits oxaliplatin-induced peripheral neuropathy
via protection of mitochondrial function. Free Radic Biol
Med 120: 13–24, 2018.
326. Yoneda K, Tanaka F, Kondo N, Hashimoto M, Takuwa T,
Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura
T, Kuribayashi K, Tabata C, Nakano T, and Hasegawa
S. Circulating tumor cell (CTC) as a prognostic marker in
primary lung cancer. J Clin Oncol 33: e22041, 2015.
327. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting
DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM,
Concannon KF, Donaldson MC, Sequist LV, Brachtel E,
Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA,
and Maheswaran S. Circulating breast tumor cells exhibit
dynamic changes in epithelial and mesenchymal compo-
sition. Science 339: 580–584, 2013.
328. Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, Yu S,
Oo KT, Ma J, and Kong AN. Butylated hydroxyanisole
regulates ARE-mediated gene expression via Nrf2 cou-
pled with ERK and JNK signaling pathway in HepG2
cells. Mol Carcinog 45: 841–850, 2006.
329. Yun CW and Lee SH. The roles of autophagy in cancer.
Int J Mol Sci 19: pii: E3466, 2018.
330. Zagorski JW, Turley AE, Freeborn RA, VanDenBerg KR,
Dover HE, Kardell BR, Liby KT, and Rockwell CE.
Differential effects of the Nrf2 activators tBHQ and
CDDO-Im on the early events of T cell activation. Bio-
chem Pharmacol 147: 67–76, 2018.
331. Zhang B, Xu J, Li C, Shi S, Ji S, Xu W, Liu J, Jin K, Liang
D, Liang C, Liu L, Liu C, Qin Y, and Yu X. MBD1 is an
epigenetic regulator of KEAP1 in pancreatic cancer. Curr
Mol Med 16: 404–411, 2016.
332. Zhang DD, Lo SC, Cross JV, Templeton DJ, and Hannink
M. Keap1 is a redox-regulated substrate adaptor protein
for a Cul3-dependent ubiquitin ligase complex. Mol Cell
Biol 24: 10941–10953, 2004.
333. Zhang HS, Du GY, Zhang ZG, Zhou Z, Sun HL, Yu XY,
Shi YT, Xiong DN, Li H, and Huang YH. NRF2 facilitates
breast cancer cell growth via HIF1a-mediated metabolic
reprogramming. Int J Biochem Cell Biol 95: 85–92, 2018.
334. Zhang HS, Zhang ZG, Du GY, Sun HL, Liu HY, Zhou Z,
Gou XM, Wu XH, Yu XY, and Huang YH. Nrf2 promotes
breast cancer cell migration via up-regulation of G6PD/
HIF-1alpha/Notch1 axis. J Cell Mol Med 23: 3451–3463,
2019.
335. This reference has been deleted.
336. Zhang J, Jiao Q, Kong L, Yu J, Fang A, Li M, and Yu
J. Nrf2 and Keap1 abnormalities in esophageal squamous
cell carcinoma and association with the effect of che-
moradiotherapy. Thorac Cancer 9: 726–735, 2018.
337. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kom-
bairaju P, Bodas M, Wu H, Bova SG, and Biswal S. Loss
of Kelch-like ECH-associated protein 1 function in pros-
tate cancer cells causes chemoresistance and radio-
resistance and promotes tumor growth. Mol Cancer Ther
9: 336–346, 2010.
338. Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi
K, Li X, Wei Y, Lee H, Zhuang L, Chen G, Xiao Z-D,
Hung M-C, Chen J, Huang P, Li W, and Gan B. BAP1
links metabolic regulation of ferroptosis to tumour sup-
pression. Nat Cell Biol 20: 1181–1192, 2018.
339. Zhang Z, Wang Q, Ma J, Yi X, Zhu Y, Xi X, Feng Y, and
Jin Z. Reactive oxygen species regulate FSH-induced
expression of vascular endothelial growth factor via Nrf2
and HIF1alpha signaling in human epithelial ovarian
cancer. Oncol Rep 29: 1429–1434, 2013.
340. Zhao M, Xu H, Zhang B, Hong B, Yan W, and Zhang
J. Impact of nuclear factor erythroid-derived 2-like 2 and
p62/sequestosome expression on prognosis of patients
with gliomas. Hum Pathol 46: 843–849, 2015.
341. Zhou C, Zhao L, Zheng J, Wang K, Deng H, Liu P, Chen
L, and Mu H. MicroRNA-144 modulates oxidative stress
tolerance in SH-SY5Y cells by regulating nuclear factor
erythroid 2-related factor 2-glutathione axis. Neurosci Lett
655: 21–27, 2017.
342. Zhou L, Ao L, Yan Y, Li C, Li W, Ye A, Liu J, Hu Y,
Fang W, and Li Y. Levo-corydalmine attenuates
vincristine-induced neuropathic pain in mice by upregu-
30 SMOLKOVA´ ET AL.
lating the Nrf2/HO-1/CO pathway to inhibit Connexin 43
expression. Neurotherapeutics 17: 340–355, 2020.
343. Zhou L, Zhang H, Davies KJA, and Forman HJ. Aging-
related decline in the induction of Nrf2-regulated antiox-
idant genes in human bronchial epithelial cells. Redox
Biol 14:35–40, 2018.
344. Zhou S, Ye W, Zhang Y, Yu D, Shao Q, Liang J, and
Zhang M. miR-144 reverses chemoresistance of hepato-
cellular carcinoma cell lines by targeting Nrf2-dependent
antioxidant pathway. Am J Transl Res 8: 2992–3002,
2016.
345. Zhou Z, Xu J, Bao X, Shi J, Liu B, Chen Y, and Li
J. Nuclear Nrf2 activity in laryngeal carcinoma is regu-
lated by SENP3 after cisplatin-induced reactive oxygen
species stress. J Cancer 10: 3427–3434, 2019.
346. Zhu M and Fahl WE. Functional characterization of
transcription regulators that interact with the electrophile
response element. Biochem Biophys Res Commun 289:
212–219, 2001.
347. Zipper LM and Mulcahy RT. The Keap1 BTB/POZ di-
merization function is required to sequester Nrf2 in cy-
toplasm. J Biol Chem 277: 36544–36552, 2002.
Address correspondence to:
Prof. Pe´ter Bai
Department of Medical Chemistry
Faculty of Medicine
University of Debrecen
Egyetem te´r 1.
Debrecen 4032
Hungary
E-mail: baip@med.unideb.hu
Dr. Katarı´na Smolkova´
Department of Mitochondrial Physiology
Institute of Physiology of the Czech Academy of Sciences
(IPHYS CAS)
No. 75
Vı´denˇska´ 1083
Prague 14220
Czech Republic
E-mail: katarina.smolkova@fgu.cas.cz
Date of first submission to ARS Central, January 13, 2020;
date of final revised submission, January 20, 2020; date of
acceptance, January 20, 2020.
Abbreviations Used
4-OHE2¼ 4-Hydroxyestradiol
15d-PGJ2¼ 15-deoxy-prostaglandin J2
AKT¼ protein kinase B
ALDH1¼ aldehyde-dehydrogenase 1
AMER1¼Wilms tumor gene on the X chromosome
AML¼ acute myeloid leukemia
AMPK¼AMP-activated protein kinase
ARE¼ antioxidant response element
ATF4¼ activating transcription factor 4
b-TrCP¼ b-transducin repeat-containing protein
Bach1¼BTB and CNC homology 1
BAP1¼BRCA1 associated protein 1
BRCA1¼ breast cancer type 1 susceptibility protein
BRCA2¼ breast cancer type 2 susceptibility protein
BRD4¼ bromodomain protein 4
BTB¼Broad complex/Tramtrack/Bric-a-brac
bZIP¼ basic leucine zipper domain
Cav-1¼ caveolin-1
CDK20¼ cyclin-dependent kinase 20
CDO1¼ cysteine dioxygenase 1
CHD6¼ chromodomain helicase DNA binding protein 6
COX-2¼ cyclooxygenase-2
CSC¼ cancer stem cell
CTCs¼ circulating tumor cells
CTR¼ carboxy-terminal
Cul3¼ cullin 3
DGR¼ double glycine repeats
DPP3¼ dipeptidyl peptidase 3
E/M¼ epithelial/mesenchymal
EMT¼ epithelial-mesenchymal transition
EpRE¼ electrophilic response element
ERK¼ extracellular signal–regulated kinase
FAM129B¼ family with sequence similarity 129, member B
FH¼ fumarate hydratase
G6pd¼ glucose-6-phosphate dehydrogenase
GCL¼ glutamate-cysteine ligase
GCLC¼ glutamate-cysteine ligase catalytic
GCLM¼ glutamate-cysteine ligase modifier
Gpx2¼ glutathione peroxidase 2
GRP78¼ heat shock 70kDa protein 5
GSH¼ reduced glutathione
GSK3¼ glycogen synthase kinase 3
GSK3b¼ glycogen synthase kinase 3b
Gsr1¼ glutathione reductase 1
GSSG¼ oxidized glutathione
GST¼ glutathione S-transferase
HCC¼ hepatocellular carcinoma
HER2¼ human epidermal growth receptor 2, HER2/
neu, cErbb2
HIF1a¼ hypoxia-inducible factor 1a
HMOX1¼ heme oxygenase (decycling) 1
Idh1¼ isocitrate dehydrogenase 1
IVR¼ intervening region
KEAP1¼Kelch-like ECH-associated protein 1
KHK-A¼ ketohexokinase-A
LCA¼ lithocholic acid
LOF¼ loss-of-function
MAT¼methionine adenosyltransferase
MAT2A¼methionine adenosyltransferase 2A
Me1¼malic enzyme 1
MEK¼mitogen activated protein kinase kinase
MET¼mesenchymal–epithelial transition
MICA¼ not defined as abbreviation
miRNA¼microRNA
MnSOD¼manganese-dependent superoxide dismutase
Mrps¼multidrug-resistance-associated transporters
Mrp1¼multidrug resistance-associated protein 1
MSLP¼maximum species lifespan potential
mTORC1¼mechanistic (or mammalian) target
of rapamycin complex 1
N/A¼ not applicable
NFE2¼ nuclear factor erythroid 2
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Abbreviations Used (Cont.)
Neh¼NRF2-ECH homology
NQO1¼NAD(P)H quinone dehydrogenase 1
NRF2¼NFE2-related factor 2 (Nfe2l2, commonly
called NRF2)
NSCLC¼ nonsmall-cell lung carcinoma
OGG1¼ 8-Oxoguanine glycosylase
OTUB1¼ ovarian tumor family member deubiquitinase
p62¼ sequestosome 1
PALB2¼ partner and localizer of BRCA2
PDAC¼ pancreatic ductal adenocarcinoma
PERK¼ protein kinase R-like endoplasmic reticulum
kinase
Pgd¼ 6-phosphogluconate dehydrogenase
PI3K¼ phosphoinositide 3-kinases
PPP¼ pentose-phosphate pathway
PUFA¼ polyunsaturated fatty acid
RARa¼ retinoic acid receptor X receptor a
ROS¼ oxygen-centered reactive species
RXRa¼ retinoid X receptor a
SLC7A11¼ solute carrier family 7 member 11
Srxn1¼ sulfiredoxin 1
TAMR¼ tamoxifen-resistant
TCA¼ tricarboxylic acid cycle
TKT¼ transketolase
TP53¼ gene encoding for tumor protein P53
Txn1¼ thioredoxin 1
Txnrd1¼ thioredoxin reductase 1
UHRF1¼ ubiquitin-like, containing PHD and RING
finger domains-1
UPR¼ unfolded protein response
VEGF¼ vascular endothelial growth factor
WTX¼Wilms tumor gene on the X chromosome
xCT¼ protein encoded by SLC7A11
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